Tumors affecting adolescents and young adults often differ from those affecting pediatric and older adult populations. For this reason, a classification scheme has been proposed for tumors diagnosed in adolescents and young adults. This classification scheme was updated based on site and histology codes of the International Classification of Diseases for Oncology, Third Edition. Effective 2001, all cases reported to SEER were required to have an ICD-O-3 histology and behavior code and all previous cases were converted to ICD-O-3. In addition, although benign brain tumors have also been reported to SEER since 2004, not enough time has elapsed to present rates and trend data for these tumors. These site/histology groupings, however, are not comparable with the groupings of ICD-10 for mortality. Therefore, for incidence and mortality comparisons, the SEER site recode as described in the appendix was used. In this chapter, the incidence of malignant cancers in adolescent and young adults, 15 to 39 years of age, are presented based on the 2 different classification schemes described above.

REFERENCES:


Table 32.1
Age-Adjusted SEER Incidence*, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adultsb
All Races, 2010-2014

<table>
<thead>
<tr>
<th>Site</th>
<th>All Sites Combined</th>
<th>Ages 0-14</th>
<th>Ages 15-39</th>
<th>Ages 40+</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>1. LEUKEMIAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1 Acute lymphoid leukemia</td>
<td>5.5</td>
<td>4.9</td>
<td>3.9</td>
<td>2.9</td>
</tr>
<tr>
<td>1.2 Acute myeloid leukemia</td>
<td>4.3</td>
<td>3.9</td>
<td>1.2</td>
<td>0.7</td>
</tr>
<tr>
<td>1.3 Chronic myeloid leukemia</td>
<td>0.9</td>
<td>0.8</td>
<td>1.3</td>
<td>1.4</td>
</tr>
<tr>
<td>1.4 Other and unspecified leukemias</td>
<td>0.1</td>
<td>0.1</td>
<td>0.8</td>
<td>0.5</td>
</tr>
<tr>
<td>2. LYMPHOMAS</td>
<td>2.1</td>
<td>1.1</td>
<td>8.2</td>
<td>6.6</td>
</tr>
<tr>
<td>2.1 Non-Hodgkin Lymphoma</td>
<td>1.4</td>
<td>0.7</td>
<td>4.7</td>
<td>3.2</td>
</tr>
<tr>
<td>2.2 Hodgkin Lymphoma</td>
<td>0.7</td>
<td>0.4</td>
<td>3.5</td>
<td>3.4</td>
</tr>
<tr>
<td>3. CNS, INTRACRANIAL, INTRASPINAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.1 Astrocytoma</td>
<td>1.7</td>
<td>1.7</td>
<td>1.8</td>
<td>1.3</td>
</tr>
<tr>
<td>3.1.1 Specified low-grade astrocytic tumors</td>
<td>1.2</td>
<td>1.2</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>3.1.2 Glioblastoma and anaplastic astrocytoma</td>
<td>0.3</td>
<td>0.3</td>
<td>1.0</td>
<td>0.7</td>
</tr>
<tr>
<td>3.1.3 Astrocytoma, NOS</td>
<td>0.2</td>
<td>0.2</td>
<td>0.4</td>
<td>0.3</td>
</tr>
<tr>
<td>3.2 Other glioma</td>
<td>0.5</td>
<td>0.5</td>
<td>0.9</td>
<td>0.7</td>
</tr>
<tr>
<td>3.3 Ependymoma</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>3.4 Medulloblastoma and other PNET</td>
<td>0.7</td>
<td>0.4</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>3.4.1 Medulloblastoma</td>
<td>0.5</td>
<td>0.3</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>3.4.2 Supratentorial PNET</td>
<td>0.2</td>
<td>0.2</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>3.5 Other specified intracranial and intraspinal neoplasms</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>3.6 Unspecified intracranial and intraspinal neoplasms</td>
<td>-</td>
<td>0.0</td>
<td>0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>4. OSSEOUS &amp; CHONDROMATOUS NEOPLASMS</td>
<td>0.9</td>
<td>0.8</td>
<td>1.1</td>
<td>0.8</td>
</tr>
<tr>
<td>4.1 Osteosarcoma</td>
<td>0.4</td>
<td>0.4</td>
<td>0.4</td>
<td>0.3</td>
</tr>
<tr>
<td>4.2 Chondrosarcoma</td>
<td>0.0</td>
<td>-</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>4.3 Ewing tumor</td>
<td>0.4</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>4.4 Other specified and unspecified bone tumors</td>
<td>0.0</td>
<td>-</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>5. SOFT TISSUE SARCOMAS</td>
<td>1.1</td>
<td>0.9</td>
<td>3.2</td>
<td>2.3</td>
</tr>
<tr>
<td>5.1 Fibromatous neoplasms</td>
<td>0.2</td>
<td>0.1</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>5.2 Rhabdomyosarcoma</td>
<td>0.6</td>
<td>0.4</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>5.3 Other specified soft tissue sarcoma</td>
<td>0.3</td>
<td>0.3</td>
<td>2.4</td>
<td>1.5</td>
</tr>
<tr>
<td>5.3.1 Specified soft tissue sarcoma</td>
<td>0.2</td>
<td>0.2</td>
<td>2.0</td>
<td>1.1</td>
</tr>
<tr>
<td>5.3.1.1 Specified (excluding Kaposi sarcoma)</td>
<td>0.2</td>
<td>0.2</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>5.3.1.2 Kaposi sarcoma</td>
<td>-</td>
<td>-</td>
<td>0.9</td>
<td>0.0</td>
</tr>
<tr>
<td>5.3.2 Unspecified soft tissue sarcoma</td>
<td>0.1</td>
<td>0.1</td>
<td>0.4</td>
<td>0.3</td>
</tr>
<tr>
<td>6. GERM CELL AND TROPHOBLASTIC NEOPLASMS</td>
<td>0.5</td>
<td>0.7</td>
<td>11.2</td>
<td>1.0</td>
</tr>
<tr>
<td>6.1 Germ cell and trophoblastic neoplasms of gonads</td>
<td>0.2</td>
<td>0.3</td>
<td>10.8</td>
<td>0.7</td>
</tr>
<tr>
<td>6.2 Germ cell and trophoblastic neoplasms of nongonadal sites</td>
<td>0.3</td>
<td>0.3</td>
<td>0.5</td>
<td>0.3</td>
</tr>
<tr>
<td>6.2.1 Intracranial sites</td>
<td>0.2</td>
<td>0.1</td>
<td>0.2</td>
<td>-</td>
</tr>
<tr>
<td>6.2.2 Other nongonadal sites</td>
<td>0.1</td>
<td>0.2</td>
<td>0.3</td>
<td>0.3</td>
</tr>
</tbody>
</table>

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose–Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
### Table 32.1 - continued

#### Age-Adjusted SEER Incidence*, by Age Group and Sex

By Adapted Classification Scheme for Tumors of Adolescents and Young Adults

All Races, 2010-2014

<table>
<thead>
<tr>
<th>Site</th>
<th>Ages 0-14 Male</th>
<th>Ages 0-14 Female</th>
<th>Ages 15-39 Male</th>
<th>Ages 15-39 Female</th>
<th>Ages 40+ Male</th>
<th>Ages 40+ Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>7. MELANOMA AND SKIN CARCINOMAS</td>
<td>0.2</td>
<td>0.2</td>
<td>5.1</td>
<td>8.6</td>
<td>70.1</td>
<td>37.1</td>
</tr>
<tr>
<td>7.1 Melanoma</td>
<td>0.2</td>
<td>0.2</td>
<td>5.0</td>
<td>8.5</td>
<td>65.7</td>
<td>35.0</td>
</tr>
<tr>
<td>7.2 Skin carcinosmas</td>
<td>-</td>
<td>-</td>
<td>0.1</td>
<td>0.1</td>
<td>4.3</td>
<td>2.1</td>
</tr>
<tr>
<td>8. CARCINOMAS (excluding skin)</td>
<td>0.5</td>
<td>0.9</td>
<td>17.0</td>
<td>61.3</td>
<td>837.1</td>
<td>709.1</td>
</tr>
<tr>
<td>8.1 Thyroid carcinoma</td>
<td>0.2</td>
<td>0.5</td>
<td>3.9</td>
<td>18.3</td>
<td>13.0</td>
<td>33.2</td>
</tr>
<tr>
<td>8.2 Other carcinoma of head and neck</td>
<td>0.1</td>
<td>0.1</td>
<td>1.7</td>
<td>1.4</td>
<td>51.5</td>
<td>16.3</td>
</tr>
<tr>
<td>8.2.1 Nasopharyngeal carcinoma</td>
<td>0.0</td>
<td>-</td>
<td>0.3</td>
<td>0.2</td>
<td>1.8</td>
<td>0.6</td>
</tr>
<tr>
<td>8.2.2 Other sites in lip, oral cavity and pharynx</td>
<td>0.1</td>
<td>0.1</td>
<td>1.2</td>
<td>1.1</td>
<td>35.2</td>
<td>12.3</td>
</tr>
<tr>
<td>8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck</td>
<td>-</td>
<td>-</td>
<td>0.3</td>
<td>0.1</td>
<td>14.5</td>
<td>3.4</td>
</tr>
<tr>
<td>8.3 Carcinoma of trachea, bronchus, and lung</td>
<td>-</td>
<td>-</td>
<td>0.9</td>
<td>1.0</td>
<td>139.4</td>
<td>103.0</td>
</tr>
<tr>
<td>8.4 Carcinoma of breast</td>
<td>-</td>
<td>-</td>
<td>0.1</td>
<td>21.0</td>
<td>2.7</td>
<td>269.2</td>
</tr>
<tr>
<td>8.5 Carcinoma of genitourinary tract</td>
<td>0.0</td>
<td>0.1</td>
<td>3.6</td>
<td>13.2</td>
<td>402.2</td>
<td>135.5</td>
</tr>
<tr>
<td>8.5.1 Carcinoma of kidney</td>
<td>-</td>
<td>-</td>
<td>2.4</td>
<td>1.7</td>
<td>43.6</td>
<td>20.9</td>
</tr>
<tr>
<td>8.5.2 Carcinoma of bladder</td>
<td>-</td>
<td>-</td>
<td>0.8</td>
<td>0.3</td>
<td>79.0</td>
<td>18.8</td>
</tr>
<tr>
<td>8.5.3 Carcinoma of gonads</td>
<td>-</td>
<td>-</td>
<td>0.0</td>
<td>1.8</td>
<td>0.0</td>
<td>21.9</td>
</tr>
<tr>
<td>8.5.4 Carcinoma of cervix and uterus</td>
<td>-</td>
<td>-</td>
<td>8.9</td>
<td>-</td>
<td>62.5</td>
<td></td>
</tr>
<tr>
<td>8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract</td>
<td>-</td>
<td>-</td>
<td>0.3</td>
<td>0.4</td>
<td>279.5</td>
<td>11.4</td>
</tr>
<tr>
<td>8.6 Carcinoma of gastrointestinal tract</td>
<td>0.1</td>
<td>0.1</td>
<td>6.4</td>
<td>5.9</td>
<td>212.4</td>
<td>137.8</td>
</tr>
<tr>
<td>8.6.1 Carcinoma of colon and rectum</td>
<td>0.1</td>
<td>0.1</td>
<td>4.2</td>
<td>4.0</td>
<td>104.1</td>
<td>80.8</td>
</tr>
<tr>
<td>8.6.2 Carcinoma of stomach</td>
<td>-</td>
<td>-</td>
<td>0.7</td>
<td>0.7</td>
<td>20.6</td>
<td>10.1</td>
</tr>
<tr>
<td>8.6.3 Carcinoma of liver and intrahepatic bile ducts</td>
<td>0.1</td>
<td>-</td>
<td>0.5</td>
<td>0.3</td>
<td>28.7</td>
<td>9.6</td>
</tr>
<tr>
<td>8.6.4 Carcinoma of pancreas</td>
<td>-</td>
<td>-</td>
<td>0.4</td>
<td>0.5</td>
<td>28.9</td>
<td>22.1</td>
</tr>
<tr>
<td>8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract</td>
<td>-</td>
<td>-</td>
<td>0.6</td>
<td>0.4</td>
<td>30.1</td>
<td>15.3</td>
</tr>
<tr>
<td>8.7 Carcinoma of other and ill-defined sites, NOS</td>
<td>0.1</td>
<td>0.0</td>
<td>0.4</td>
<td>0.5</td>
<td>15.9</td>
<td>14.1</td>
</tr>
<tr>
<td>8.7.1 Adrenocortical carcinoma</td>
<td>0.0</td>
<td>-</td>
<td>0.0</td>
<td>0.1</td>
<td>0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>8.7.2 Carcinoma of other and ill-defined sites, NOS</td>
<td>-</td>
<td>-</td>
<td>0.4</td>
<td>0.5</td>
<td>15.7</td>
<td>13.8</td>
</tr>
<tr>
<td>9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS</td>
<td>2.8</td>
<td>2.9</td>
<td>0.9</td>
<td>1.3</td>
<td>27.1</td>
<td>21.9</td>
</tr>
<tr>
<td>9.1 Other pediatric and embryonal tumors, NOS</td>
<td>2.7</td>
<td>2.8</td>
<td>0.1</td>
<td>0.1</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>9.1.1 Wilms tumor</td>
<td>0.7</td>
<td>0.8</td>
<td>-</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>9.1.2 Neuroblastoma</td>
<td>1.0</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>9.1.3 Other pediatric and embryonal tumors, NOS</td>
<td>1.0</td>
<td>0.9</td>
<td>0.1</td>
<td>0.0</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>9.2 Other specified neoplasms, NOS</td>
<td>0.1</td>
<td>0.1</td>
<td>0.8</td>
<td>1.2</td>
<td>26.9</td>
<td>21.7</td>
</tr>
<tr>
<td>9.2.1 Parangangioma and glomus tumors</td>
<td>-</td>
<td>-</td>
<td>0.1</td>
<td>0.0</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>9.2.2 Other specified gonadal tumors</td>
<td>-</td>
<td>-</td>
<td>0.0</td>
<td>0.2</td>
<td>0.0</td>
<td>0.4</td>
</tr>
<tr>
<td>9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS</td>
<td>0.1</td>
<td>0.0</td>
<td>0.5</td>
<td>0.3</td>
<td>20.3</td>
<td>12.7</td>
</tr>
<tr>
<td>9.2.4 Other specified neoplasms, NOS</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
<td>0.6</td>
<td>6.5</td>
<td>8.5</td>
</tr>
<tr>
<td>10. UNSPECIFIED MALIGNANT NEOPLASMS</td>
<td>-</td>
<td>-</td>
<td>0.3</td>
<td>0.5</td>
<td>36.3</td>
<td>25.9</td>
</tr>
</tbody>
</table>

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
Table 32.2

Age-Adjusted SEER Incidence*, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults\textsuperscript{b}
White, 2010-2014

<table>
<thead>
<tr>
<th>Site</th>
<th>Ages 0-14 Male</th>
<th>Ages 0-14 Female</th>
<th>Ages 15-39 Male</th>
<th>Ages 15-39 Female</th>
<th>Ages 40+ Male</th>
<th>Ages 40+ Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites Combined</td>
<td>17.8</td>
<td>16.3</td>
<td>58.3</td>
<td>92.9</td>
<td>1098.3</td>
<td>894.8</td>
</tr>
<tr>
<td>1. LEUKEMIAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1 Acute lymphoid leukemia</td>
<td>6.0</td>
<td>5.4</td>
<td>4.1</td>
<td>3.0</td>
<td>36.7</td>
<td>21.1</td>
</tr>
<tr>
<td>1.2 Acute myeloid leukemia</td>
<td>4.8</td>
<td>4.4</td>
<td>1.4</td>
<td>0.8</td>
<td>1.4</td>
<td>1.1</td>
</tr>
<tr>
<td>1.3 Chronic myeloid leukemia</td>
<td>0.9</td>
<td>0.8</td>
<td>1.4</td>
<td>1.4</td>
<td>11.6</td>
<td>7.4</td>
</tr>
<tr>
<td>1.4 Other and unspecified leukemias</td>
<td>0.2</td>
<td>0.1</td>
<td>0.8</td>
<td>0.6</td>
<td>4.7</td>
<td>2.7</td>
</tr>
<tr>
<td>2. LYMPHOMAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Non-Hodgkin Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2 Hodgkin Lymphoma</td>
<td>0.7</td>
<td>0.4</td>
<td>3.7</td>
<td>3.7</td>
<td>3.7</td>
<td>2.4</td>
</tr>
<tr>
<td>3. CNS, INTRACRANIAL, INTRASPINAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.1 Astrocytoma</td>
<td>3.6</td>
<td>3.2</td>
<td>3.7</td>
<td>2.8</td>
<td>14.3</td>
<td>9.7</td>
</tr>
<tr>
<td>3.1.1 Specified low-grade astrocytic tumors</td>
<td>1.8</td>
<td>1.8</td>
<td>2.0</td>
<td>1.5</td>
<td>11.4</td>
<td>7.4</td>
</tr>
<tr>
<td>3.1.2 Glioblastoma and anaplastic astrocytoma</td>
<td>1.3</td>
<td>1.3</td>
<td>0.5</td>
<td>0.4</td>
<td>0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>3.1.3 Astrocytoma, NOS</td>
<td>0.1</td>
<td>0.2</td>
<td>0.4</td>
<td>0.3</td>
<td>0.6</td>
<td>0.4</td>
</tr>
<tr>
<td>3.2 Other glioma</td>
<td>0.5</td>
<td>0.6</td>
<td>1.0</td>
<td>0.8</td>
<td>1.6</td>
<td>1.1</td>
</tr>
<tr>
<td>3.3 Ependymoma</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
<td>0.2</td>
<td>0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>3.4 Medulloblastoma and other PNET</td>
<td>0.8</td>
<td>0.4</td>
<td>0.3</td>
<td>0.2</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>3.4.1 Medulloblastoma</td>
<td>0.5</td>
<td>0.2</td>
<td>0.1</td>
<td>0.1</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>3.4.2 Supratentorial PNET</td>
<td>0.2</td>
<td>0.2</td>
<td>0.1</td>
<td>0.1</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>3.5 Other specified intracranial and intraspinal neoplasms</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>3.6 Unspecified intracranial and intraspinal neoplasms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.7</td>
<td>0.6</td>
</tr>
<tr>
<td>4. OSSEOUS &amp; CHONDROMATOUS NEOPLASMS</td>
<td>0.9</td>
<td>0.9</td>
<td>1.2</td>
<td>0.9</td>
<td>1.6</td>
<td>1.1</td>
</tr>
<tr>
<td>4.1 Osteosarcoma</td>
<td>0.4</td>
<td>0.4</td>
<td>0.4</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>4.2 Chondrosarcoma</td>
<td>0.0</td>
<td>–</td>
<td>0.2</td>
<td>0.2</td>
<td>0.8</td>
<td>0.5</td>
</tr>
<tr>
<td>4.3 Ewing tumor</td>
<td>0.4</td>
<td>0.4</td>
<td>0.4</td>
<td>0.3</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>4.4 Other specified and unspecified bone tumors</td>
<td>–</td>
<td>–</td>
<td>0.1</td>
<td>0.1</td>
<td>0.4</td>
<td>0.3</td>
</tr>
<tr>
<td>5. SOFT TISSUE SARCOMAS</td>
<td>1.0</td>
<td>0.9</td>
<td>2.8</td>
<td>2.2</td>
<td>13.1</td>
<td>8.9</td>
</tr>
<tr>
<td>5.1 Fibromatous neoplasms</td>
<td>0.2</td>
<td>0.1</td>
<td>0.5</td>
<td>0.6</td>
<td>2.9</td>
<td>1.5</td>
</tr>
<tr>
<td>5.2 Rhabdomyosarcoma</td>
<td>0.6</td>
<td>0.5</td>
<td>0.1</td>
<td>0.1</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>5.3 Other specified soft tissue sarcoma</td>
<td>0.3</td>
<td>0.3</td>
<td>2.1</td>
<td>1.4</td>
<td>10.1</td>
<td>7.2</td>
</tr>
<tr>
<td>5.3.1 Specified soft tissue sarcoma</td>
<td>0.2</td>
<td>0.2</td>
<td>1.7</td>
<td>1.1</td>
<td>7.1</td>
<td>5.3</td>
</tr>
<tr>
<td>5.3.1.1 Specified (excluding Kaposi sarcoma)</td>
<td>0.2</td>
<td>0.2</td>
<td>1.1</td>
<td>1.1</td>
<td>5.8</td>
<td>5.2</td>
</tr>
<tr>
<td>5.3.1.2 Kaposi sarcoma</td>
<td>–</td>
<td>–</td>
<td>0.6</td>
<td>–</td>
<td>1.3</td>
<td>0.2</td>
</tr>
<tr>
<td>5.3.2 Unspecified soft tissue sarcoma</td>
<td>0.1</td>
<td>0.1</td>
<td>0.4</td>
<td>0.3</td>
<td>3.0</td>
<td>1.9</td>
</tr>
<tr>
<td>6. GERM CELL AND TROPHOBLASTIC NEOPLASMS</td>
<td>0.5</td>
<td>0.6</td>
<td>13.5</td>
<td>0.9</td>
<td>4.8</td>
<td>0.2</td>
</tr>
<tr>
<td>6.1 Germ cell and trophoblastic neoplasms of gonads</td>
<td>0.2</td>
<td>0.3</td>
<td>13.0</td>
<td>0.6</td>
<td>4.6</td>
<td>0.1</td>
</tr>
<tr>
<td>6.2 Germ cell and trophoblastic neoplasms of nongonadal sites</td>
<td>0.3</td>
<td>0.3</td>
<td>0.5</td>
<td>0.3</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>6.2.1 Intracranial sites</td>
<td>0.2</td>
<td>0.1</td>
<td>0.2</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6.2.2 Other nongonadal sites</td>
<td>0.1</td>
<td>0.2</td>
<td>0.3</td>
<td>0.3</td>
<td>0.1</td>
<td>0.1</td>
</tr>
</tbody>
</table>

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
### Table 32.2 - continued

#### Age-Adjusted SEER Incidence*, by Age Group and Sex

By Adapted Classification Scheme for Tumors of Adolescents and Young Adults

White, 2010-2014

<table>
<thead>
<tr>
<th>Site</th>
<th>Ages 0-14</th>
<th>Ages 15-39</th>
<th>Ages 40+</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>7. MELANOMA AND SKIN CARCINOMAS</td>
<td>0.2</td>
<td>0.3</td>
<td>6.3</td>
</tr>
<tr>
<td>7.1 Melanoma</td>
<td>0.2</td>
<td>0.3</td>
<td>6.2</td>
</tr>
<tr>
<td>7.2 Skin carcinomas</td>
<td>-</td>
<td>-</td>
<td>0.1</td>
</tr>
<tr>
<td>8. CARCINOMAS (excluding skin)</td>
<td>0.6</td>
<td>1.0</td>
<td>17.3</td>
</tr>
<tr>
<td>8.1 Thyroid carcinoma</td>
<td>0.2</td>
<td>0.6</td>
<td>4.3</td>
</tr>
<tr>
<td>8.2 Other carcinoma of head and neck</td>
<td>0.1</td>
<td>0.1</td>
<td>1.7</td>
</tr>
<tr>
<td>8.2.1 Nasopharyngeal carcinoma</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
</tr>
<tr>
<td>8.2.2 Other sites in lip, oral cavity and pharynx</td>
<td>0.1</td>
<td>0.1</td>
<td>1.2</td>
</tr>
<tr>
<td>8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck</td>
<td>-</td>
<td>-</td>
<td>0.3</td>
</tr>
<tr>
<td>8.3 Carcinoma of trachea, bronchus, and lung</td>
<td>-</td>
<td>-</td>
<td>0.9</td>
</tr>
<tr>
<td>8.4 Carcinoma of breast</td>
<td>-</td>
<td>-</td>
<td>0.1</td>
</tr>
<tr>
<td>8.5 Carcinoma of genitourinary tract</td>
<td>0.0</td>
<td>0.1</td>
<td>3.7</td>
</tr>
<tr>
<td>8.5.1 Carcinoma of kidney</td>
<td>-</td>
<td>-</td>
<td>2.5</td>
</tr>
<tr>
<td>8.5.2 Carcinoma of bladder</td>
<td>-</td>
<td>-</td>
<td>0.9</td>
</tr>
<tr>
<td>8.5.3 Carcinoma of gonads</td>
<td>-</td>
<td>-</td>
<td>0.0</td>
</tr>
<tr>
<td>8.5.4 Carcinoma of cervix and uterus</td>
<td>-</td>
<td>-</td>
<td>9.4</td>
</tr>
<tr>
<td>8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract</td>
<td>-</td>
<td>-</td>
<td>0.3</td>
</tr>
<tr>
<td>8.6 Carcinoma of gastrointestinal tract</td>
<td>0.2</td>
<td>0.1</td>
<td>6.3</td>
</tr>
<tr>
<td>8.6.1 Carcinoma of colon and rectum</td>
<td>0.1</td>
<td>0.1</td>
<td>4.2</td>
</tr>
<tr>
<td>8.6.2 Carcinoma of stomach</td>
<td>-</td>
<td>-</td>
<td>0.7</td>
</tr>
<tr>
<td>8.6.3 Carcinoma of liver and intrahepatic bile ducts</td>
<td>0.1</td>
<td>-</td>
<td>0.3</td>
</tr>
<tr>
<td>8.6.4 Carcinoma of pancreas</td>
<td>-</td>
<td>-</td>
<td>0.4</td>
</tr>
<tr>
<td>8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract</td>
<td>-</td>
<td>-</td>
<td>0.6</td>
</tr>
<tr>
<td>8.7 Carcinoma of other and ill-defined sites, NOS</td>
<td>-</td>
<td>0.1</td>
<td>0.4</td>
</tr>
<tr>
<td>8.7.1 Adrenocortical carcinoma</td>
<td>-</td>
<td>-</td>
<td>0.0</td>
</tr>
<tr>
<td>8.7.2 Carcinoma of other and ill-defined sites, NOS</td>
<td>-</td>
<td>-</td>
<td>0.4</td>
</tr>
<tr>
<td>9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS</td>
<td>2.9</td>
<td>2.9</td>
<td>0.8</td>
</tr>
<tr>
<td>9.1 Other pediatric and embryonal tumors, NOS</td>
<td>2.8</td>
<td>2.8</td>
<td>0.1</td>
</tr>
<tr>
<td>9.1.1 Wilms tumor</td>
<td>0.7</td>
<td>0.8</td>
<td>-</td>
</tr>
<tr>
<td>9.1.2 Neuroblastoma</td>
<td>1.1</td>
<td>1.0</td>
<td>-</td>
</tr>
<tr>
<td>9.1.3 Other pediatric and embryonal tumors, NOS</td>
<td>1.0</td>
<td>0.9</td>
<td>0.1</td>
</tr>
<tr>
<td>9.2 Other specified neoplasms, NOS</td>
<td>0.1</td>
<td>0.1</td>
<td>0.7</td>
</tr>
<tr>
<td>9.2.1 Paraganglioma and glomus tumors</td>
<td>-</td>
<td>-</td>
<td>0.1</td>
</tr>
<tr>
<td>9.2.2 Other specified gonadal tumors</td>
<td>-</td>
<td>-</td>
<td>0.0</td>
</tr>
<tr>
<td>9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS</td>
<td>0.1</td>
<td>-</td>
<td>0.4</td>
</tr>
<tr>
<td>9.2.4 Other specified neoplasms, NOS</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
</tr>
</tbody>
</table>

10. UNSPECIFIED MALIGNANT NEOPLASMS

- - 0.3 0.5 35.5 26.2

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose–Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
<table>
<thead>
<tr>
<th>Site</th>
<th>Male 0-14</th>
<th>Female 0-14</th>
<th>Male 15-39</th>
<th>Female 15-39</th>
<th>Male 40+</th>
<th>Female 40+</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites Combined</td>
<td>13.3</td>
<td>13.3</td>
<td>40.6</td>
<td>71.3</td>
<td>1237.4</td>
<td>858.1</td>
</tr>
<tr>
<td>1. LEUKEMIAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1 Acute lymphoid leukemia</td>
<td>3.4</td>
<td>2.9</td>
<td>2.8</td>
<td>2.6</td>
<td>28.6</td>
<td>16.9</td>
</tr>
<tr>
<td>1.2 Acute myeloid leukemia</td>
<td>2.3</td>
<td>2.1</td>
<td>0.6</td>
<td>0.4</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>1.3 Chronic myeloid leukemia</td>
<td>0.7</td>
<td>0.6</td>
<td>1.1</td>
<td>1.3</td>
<td>9.5</td>
<td>6.4</td>
</tr>
<tr>
<td>1.4 Other and unspecified leukemias</td>
<td>-</td>
<td>-</td>
<td>0.7</td>
<td>0.6</td>
<td>3.9</td>
<td>2.7</td>
</tr>
<tr>
<td>2. LYMPHOMAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Non-Hodgkin Lymphoma</td>
<td>1.3</td>
<td>0.8</td>
<td>5.7</td>
<td>3.7</td>
<td>35.6</td>
<td>24.9</td>
</tr>
<tr>
<td>2.2 Hodgkin Lymphoma</td>
<td>0.7</td>
<td>0.5</td>
<td>3.7</td>
<td>3.0</td>
<td>3.8</td>
<td>2.4</td>
</tr>
<tr>
<td>3. CNS, INTRACRANIAL, INTRASPINAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.1 Astrocytoma</td>
<td>2.6</td>
<td>2.9</td>
<td>1.9</td>
<td>1.6</td>
<td>8.1</td>
<td>5.3</td>
</tr>
<tr>
<td>3.1.1 Specified low-grade astrocytic tumors</td>
<td>1.2</td>
<td>1.5</td>
<td>1.1</td>
<td>0.9</td>
<td>5.9</td>
<td>3.7</td>
</tr>
<tr>
<td>3.1.2 Glioblastoma and anaplastic astrocytoma</td>
<td>0.9</td>
<td>1.1</td>
<td>0.2</td>
<td>0.3</td>
<td>0.2</td>
<td>-</td>
</tr>
<tr>
<td>3.1.3 Astrocytoma, NOS</td>
<td>-</td>
<td>-</td>
<td>0.3</td>
<td>-</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>3.2 Other gliomas</td>
<td>0.5</td>
<td>0.6</td>
<td>0.5</td>
<td>0.4</td>
<td>0.8</td>
<td>0.6</td>
</tr>
<tr>
<td>3.3 Ependymoma</td>
<td>-</td>
<td>-</td>
<td>0.3</td>
<td>-</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>3.4 Medulloblastoma and other PNET</td>
<td>0.4</td>
<td>0.4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.4.1 Medulloblastoma</td>
<td>0.3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.4.2 Supratentorial PNET</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.5 Other specified intracranial and intraspinal neoplasms</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>3.6 Unspecified intracranial and intraspinal neoplasms</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.7</td>
<td>0.5</td>
</tr>
<tr>
<td>4. OSSEOUS &amp; CHONDROMATOUS NEOPLASMS</td>
<td>0.7</td>
<td>0.6</td>
<td>0.8</td>
<td>0.6</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>4.1 Osteosarcoma</td>
<td>0.4</td>
<td>0.5</td>
<td>0.4</td>
<td>0.3</td>
<td>0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>4.2 Chondrosarcoma</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
<td>-</td>
<td>0.4</td>
<td>0.3</td>
</tr>
<tr>
<td>4.3 Ewing tumor</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4.4 Other specified and unspecified bone tumors</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>5. SOFT TISSUE SARCOMAS</td>
<td>1.2</td>
<td>0.9</td>
<td>6.0</td>
<td>3.2</td>
<td>11.1</td>
<td>12.0</td>
</tr>
<tr>
<td>5.1 Fibromatous neoplasms</td>
<td>0.2</td>
<td>0.3</td>
<td>1.3</td>
<td>1.0</td>
<td>1.8</td>
<td>1.8</td>
</tr>
<tr>
<td>5.2 Rhabdomyosarcoma</td>
<td>0.7</td>
<td>0.3</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>5.3 Other specified soft tissue sarcoma</td>
<td>0.3</td>
<td>0.3</td>
<td>4.5</td>
<td>2.0</td>
<td>9.0</td>
<td>9.9</td>
</tr>
<tr>
<td>5.3.1 Specified soft tissue sarcoma</td>
<td>-</td>
<td>-</td>
<td>4.2</td>
<td>1.6</td>
<td>6.8</td>
<td>7.6</td>
</tr>
<tr>
<td>5.3.1.1 Specified (excluding Kaposi sarcoma)</td>
<td>-</td>
<td>-</td>
<td>0.8</td>
<td>1.5</td>
<td>4.6</td>
<td>7.3</td>
</tr>
<tr>
<td>5.3.1.2 Kaposi sarcoma</td>
<td>-</td>
<td>-</td>
<td>3.4</td>
<td>-</td>
<td>2.2</td>
<td>0.3</td>
</tr>
<tr>
<td>5.3.2 Unspecified soft tissue sarcoma</td>
<td>-</td>
<td>-</td>
<td>0.4</td>
<td>0.4</td>
<td>2.2</td>
<td>2.3</td>
</tr>
<tr>
<td>6. GERM CELL AND TROPHOBLASTIC NEOPLASMS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.1 Germ cell and trophoblastic neoplasms of gonads</td>
<td>-</td>
<td>0.8</td>
<td>2.5</td>
<td>1.1</td>
<td>1.4</td>
<td>0.2</td>
</tr>
<tr>
<td>6.2 Germ cell and trophoblastic neoplasms of nongonadal sites</td>
<td>-</td>
<td>0.4</td>
<td>2.3</td>
<td>0.6</td>
<td>1.3</td>
<td>-</td>
</tr>
<tr>
<td>6.2.1 Intracranial sites</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6.2.2 Other nongonadal sites</td>
<td>-</td>
<td>-</td>
<td>0.4</td>
<td>-</td>
<td>0.2</td>
<td>-</td>
</tr>
</tbody>
</table>

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).

a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose–Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

b Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
### Table 32.3 - continued

#### Age-Adjusted SEER Incidence*, by Age Group and Sex

By Adapted Classification Scheme for Tumors of Adolescents and Young Adultsb

**Black, 2010-2014**

<table>
<thead>
<tr>
<th>Site</th>
<th>Ages 0-14</th>
<th>Ages 15-39</th>
<th>Ages 40+</th>
</tr>
</thead>
<tbody>
<tr>
<td>7. MELANOMA AND SKIN CARCINOMAS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.1 Melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.2 Skin carcinomas</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. CARCINOMAS (excluding skin)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1 Thyroid carcinoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2 Other carcinoma of head and neck</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.1 Nasopharyngeal carcinoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.2 Other sites in lip, oral cavity and pharynx</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3 Carcinoma of trachea, bronchus, and lung</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.4 Carcinoma of breast</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5 Carcinoma of genitourinary tract</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5.1 Carcinoma of kidney</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5.2 Carcinoma of bladder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5.3 Carcinoma of gonads</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5.4 Carcinoma of cervix and uterus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6 Carcinoma of gastrointestinal tract</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6.1 Carcinoma of colon and rectum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6.2 Carcinoma of stomach</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6.3 Carcinoma of liver and intrahepatic bile ducts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6.4 Carcinoma of pancreas</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.7 Carcinoma of other and ill-defined sites, NOS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.7.1 Adrenocortical carcinoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.7.2 Carcinoma of other and ill-defined sites, NOS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1 Other pediatric and embryonal tumors, NOS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1.1 Wilms tumor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1.2 Neuroblastoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1.3 Other pediatric and embryonal tumors, NOS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.2 Other specified neoplasms, NOS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.2.1 Paraganglioma and glomus tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.2.2 Other specified gonadal tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.2.4 Other specified neoplasms, NOS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. UNSPECIFIED MALIGNANT NEOPLASMS</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/SG).

Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

---

*Statistic could not be calculated. Rate based on less than 16 cases for the time interval.*
### Table 32.4

Age-Specific SEER Incidence*, by Age Group and Sex  
By Adapted Classification Scheme for Tumors of Adolescents and Young Adultsb  
All Races, 2010-2014

| Site | Ages 15-19 | | | |
|------|-------------|-------------|-------------|-------------|-------------|
|      | Male Female | Male Female | Male Female | Male Female | Male Female |
| All Sites Combined | 23.4 | 21.6 | 35.1 | 37.1 | 49.3 | 67.5 | 67.1 | 115.2 | 90.1 | 181.0 |
| 1. LEUKEMIAS | 3.8 | 2.6 | 3.1 | 2.3 | 3.3 | 2.5 | 3.9 | 3.1 | 5.0 | 3.9 |
| 1.1 Acute lymphoid leukemia | 2.3 | 1.2 | 1.3 | 0.6 | 0.9 | 0.6 | 0.8 | 0.5 | 0.9 | 0.7 |
| 1.2 Acute myeloid leukemia | 1.0 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.6 | 1.6 | 1.8 | 1.7 |
| 1.3 Chronic myeloid leukemia | 0.2 | 0.2 | 0.6 | 0.4 | 0.9 | 0.5 | 1.0 | 0.7 | 1.4 | 0.9 |
| 1.4 Other and unspecified leukemias | 0.2 | 0.1 | 0.2 | 0.2 | 0.3 | 0.2 | 0.5 | 0.3 | 1.0 | 0.6 |
| 2. LYMPHOMAS | 5.5 | 4.3 | 7.1 | 6.4 | 7.7 | 6.8 | 9.2 | 7.1 | 11.0 | 8.4 |
| 2.1 Non-Hodgkin Lymphoma | 2.5 | 1.2 | 3.1 | 2.1 | 3.8 | 2.8 | 5.5 | 3.9 | 8.0 | 5.8 |
| 2.2 Hodgkin Lymphoma | 3.1 | 3.0 | 4.0 | 4.3 | 3.9 | 4.0 | 3.7 | 3.2 | 3.0 | 2.6 |
| 3. CNS, INTRACRANIAL, INTRASPINAL | 2.4 | 2.1 | 2.3 | 2.0 | 3.2 | 2.6 | 3.9 | 2.8 | 4.3 | 2.9 |
| 3.1 Astrocytoma | 1.5 | 1.3 | 1.3 | 1.0 | 1.8 | 1.3 | 2.2 | 1.4 | 2.3 | 1.6 |
| 3.1.1 Specified low-grade astrocytic tumors | 0.8 | 0.7 | 0.4 | 0.4 | 0.4 | 0.3 | 0.4 | 0.3 | 0.3 | 0.3 |
| 3.1.2 Glioblastoma and anaplastic astrocytoma | 0.4 | 0.3 | 0.6 | 0.4 | 1.0 | 0.7 | 1.4 | 0.7 | 1.6 | 1.0 |
| 3.1.3 Astrocytoma, NOS | 0.3 | 0.3 | 0.3 | 0.2 | 0.4 | 0.2 | 0.4 | 0.4 | 0.4 | 0.3 |
| 3.2 Other glioma | 0.4 | 0.4 | 0.5 | 0.6 | 0.9 | 0.8 | 1.3 | 1.0 | 1.4 | 0.9 |
| 3.3 Ependymoma | 0.2 | 0.1 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 |
| 3.4 Medulloblastoma and other PNET | 0.3 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.2 | 0.2 |
| 3.4.1 Medulloblastoma | 0.2 | 0.1 | - | 0.1 | 0.1 | - | - | - | - | - |
| 3.4.2 Supratentorial PNET | 0.1 | - | 0.1 | - | 0.1 | - | - | - | - | - |
| 3.5 Other specified intracranial and intraspinal neoplasms | - | - | - | - | - | - | - | - | - | - |
| 3.6 Unspecified intracranial and intraspinal neoplasms | - | - | - | - | - | - | - | - | - | - |
| 4. OSSEOUS & CHONDROMATOUS NEOPLASMS | 1.9 | 1.2 | 1.2 | 0.8 | 0.8 | 0.8 | 0.8 | 0.5 | 0.8 | 0.8 |
| 4.1 Osteosarcoma | 1.0 | 0.6 | 0.4 | 0.3 | 0.2 | 0.3 | 0.2 | 0.1 | 0.2 | 0.2 |
| 4.2 Chondrosarcoma | 0.1 | - | 0.2 | 0.1 | 0.2 | 0.2 | 0.3 | 0.2 | 0.3 | 0.3 |
| 4.3 Ewing tumor | 0.7 | 0.4 | 0.5 | 0.2 | 0.3 | 0.2 | 0.2 | 0.1 | - | 0.2 |
| 4.4 Other specified and unspecified bone tumors | - | 0.1 | - | 0.1 | 0.2 | - | 0.1 | - | 0.2 | 0.2 |
| 5. SOFT TISSUE SARCOMAS | 1.4 | 1.3 | 2.2 | 1.6 | 3.2 | 2.1 | 4.6 | 2.8 | 4.5 | 3.5 |
| 5.1 Fibromatous neoplasms | 0.2 | 0.3 | 0.4 | 0.5 | 0.7 | 0.7 | 1.0 | 1.0 | 1.0 | 1.1 |
| 5.2 Rhabdomyosarcoma | 0.4 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | - | - | - | - |
| 5.3 Other specified soft tissue sarcoma | 0.8 | 0.7 | 1.7 | 1.0 | 2.4 | 1.3 | 3.5 | 1.7 | 3.4 | 2.4 |
| 5.3.1 Specified soft tissue sarcoma | 0.5 | 0.5 | 1.2 | 0.7 | 2.0 | 1.0 | 3.1 | 1.4 | 3.0 | 1.9 |
| 5.3.1.1 Specified (excluding Kaposi sarcoma) | 0.5 | 0.5 | 0.8 | 0.7 | 1.0 | 0.9 | 1.4 | 1.4 | 1.6 | 1.8 |
| 5.3.1.2 Kaposi sarcoma | - | - | 0.5 | - | 1.0 | - | 1.7 | - | 1.4 | - |
| 5.3.2 Unspecified soft tissue sarcoma | 0.3 | 0.2 | 0.4 | 0.2 | 0.3 | 0.3 | 0.4 | 0.3 | 0.5 | 0.5 |
| 6. GERM CELL AND TROPHOBLASTIC NEOPLASMS | 4.5 | 1.2 | 11.0 | 1.2 | 15.4 | 1.1 | 14.3 | 0.9 | 11.5 | 0.7 |
| 6.1 Germ cell and trophoblastic neoplasms of gonads | 3.8 | 1.0 | 10.3 | 0.9 | 14.9 | 0.7 | 13.9 | 0.5 | 11.3 | 0.3 |
| 6.2 Germ cell and trophoblastic neoplasms of nongonadal sites | 0.7 | 0.2 | 0.7 | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.2 | 0.4 |
| 6.2.1 Intracranial sites | 0.4 | - | 0.3 | - | 0.1 | - | - | - | - | - |
| 6.2.2 Other nongonadal sites | 0.2 | 0.1 | 0.4 | 0.3 | 0.3 | 0.4 | 0.3 | 0.4 | 0.2 | 0.4 |

*Rates are per 100,000.

a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
### Table 32.4 - continued

*Age-Specific SEER Incidence*, by Age Group and Sex
*By Adapted Classification Scheme for Tumors of Adolescents and Young Adults*

**All Races, 2010-2014**

<table>
<thead>
<tr>
<th>Site</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7. MELANOMA AND SKIN CARCINOMAS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.1 Melanoma</td>
<td>0.9</td>
<td>1.2</td>
</tr>
<tr>
<td>7.2 Skin carcinomas</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>8. CARCINOMAS (excluding skin)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1 Thyroid carcinoma</td>
<td>0.9</td>
<td>4.9</td>
</tr>
<tr>
<td>8.2 Other carcinoma of head and neck</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>8.2.1 Nasopharyngeal carcinoma</td>
<td>0.2</td>
<td>-</td>
</tr>
<tr>
<td>8.2.2 Other sites in lip, oral cavity and pharynx</td>
<td>0.2</td>
<td>0.4</td>
</tr>
<tr>
<td>8.2.3 Paraganglioma and glomus tumors</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1 Other pediatric and embryonal tumors, NOS</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>10. UNSPECIFIED MALIGNANT NEOPLASMS</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Male 2014**

<table>
<thead>
<tr>
<th>Site</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7. MELANOMA AND SKIN CARCINOMAS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.1 Melanoma</td>
<td>0.9</td>
<td>1.2</td>
</tr>
<tr>
<td>7.2 Skin carcinomas</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>8. CARCINOMAS (excluding skin)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1 Thyroid carcinoma</td>
<td>0.9</td>
<td>4.9</td>
</tr>
<tr>
<td>8.2 Other carcinoma of head and neck</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>8.2.1 Nasopharyngeal carcinoma</td>
<td>0.2</td>
<td>-</td>
</tr>
<tr>
<td>8.2.2 Other sites in lip, oral cavity and pharynx</td>
<td>0.2</td>
<td>0.4</td>
</tr>
<tr>
<td>8.2.3 Paraganglioma and glomus tumors</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1 Other pediatric and embryonal tumors, NOS</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>10. UNSPECIFIED MALIGNANT NEOPLASMS</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Rates are per 100,000.*

- **SEER 18 areas** (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose–Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
- **Adapted from:** RD Barr, EJ Holowaty, JM Birch. *Classification Scheme for tumors diagnosed in adolescents and young adults*. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).
- Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O-3.
- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
## Table 32.5
Age-Specific SEER Incidence*, by Age Group and Sex

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male Female</td>
<td>Male Female</td>
<td>Male Female</td>
<td>Male Female</td>
<td>Male Female</td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>25.4 23.4</td>
<td>30.7 41.1</td>
<td>54.2 72.9</td>
<td>71.7 122.1</td>
<td>95.2 188.0</td>
</tr>
<tr>
<td>1. LEUKEMIAS</td>
<td>4.2 2.8</td>
<td>3.4 2.4</td>
<td>3.4 2.7</td>
<td>4.1 3.1</td>
<td>5.2 4.0</td>
</tr>
<tr>
<td>1.1 Acute lymphoid leukemia</td>
<td>2.7 1.4</td>
<td>1.5 0.7</td>
<td>1.1 0.7</td>
<td>0.9 0.5</td>
<td>1.0 0.7</td>
</tr>
<tr>
<td>1.2 Acute myeloid leukemia</td>
<td>1.1 1.1</td>
<td>1.1 1.2</td>
<td>1.2 1.3</td>
<td>1.7 1.5</td>
<td>1.8 1.7</td>
</tr>
<tr>
<td>1.3 Chronic myeloid leukemia</td>
<td>0.2 0.2</td>
<td>0.6 0.3</td>
<td>0.8 0.5</td>
<td>1.1 0.7</td>
<td>1.4 0.9</td>
</tr>
<tr>
<td>1.4 Other and unspecified leukemias</td>
<td>0.3 -</td>
<td>0.2 -</td>
<td>0.3 0.2</td>
<td>0.5 0.3</td>
<td>1.0 0.6</td>
</tr>
<tr>
<td>2. LYMPHOMAS</td>
<td>5.7 4.7</td>
<td>7.3 6.7</td>
<td>7.8 7.1</td>
<td>9.1 7.2</td>
<td>11.0 8.4</td>
</tr>
<tr>
<td>2.1 Non-Hodgkin Lymphoma</td>
<td>2.4 1.3</td>
<td>3.0 2.1</td>
<td>3.7 2.7</td>
<td>5.2 3.8</td>
<td>7.9 5.7</td>
</tr>
<tr>
<td>2.2 Hodgkin Lymphoma</td>
<td>3.3 3.4</td>
<td>4.3 4.6</td>
<td>4.1 4.4</td>
<td>3.9 3.5</td>
<td>3.1 2.7</td>
</tr>
<tr>
<td>3. CNS, INTRACRANIAL, INTRASPINAL</td>
<td>2.5 2.2</td>
<td>2.6 2.3</td>
<td>3.7 3.1</td>
<td>4.4 3.2</td>
<td>4.8 3.2</td>
</tr>
<tr>
<td>3.1 Astrocytoma</td>
<td>1.5 1.3</td>
<td>1.5 1.2</td>
<td>2.0 1.5</td>
<td>2.4 1.7</td>
<td>2.6 1.7</td>
</tr>
<tr>
<td>3.1.1 Specified low-grade astrocytic tumors</td>
<td>0.9 0.7</td>
<td>0.5 0.5</td>
<td>0.4 0.4</td>
<td>0.5 0.4</td>
<td>0.3 0.3</td>
</tr>
<tr>
<td>3.1.2 Glioblastoma and anaplastic astrocytoma</td>
<td>0.4 0.4</td>
<td>0.6 0.4</td>
<td>1.2 0.8</td>
<td>1.4 0.9</td>
<td>1.8 1.1</td>
</tr>
<tr>
<td>3.1.3 Astrocytoma, NOS</td>
<td>0.3 0.3</td>
<td>0.4 0.2</td>
<td>0.5 0.3</td>
<td>0.4 0.5</td>
<td>0.4 0.3</td>
</tr>
<tr>
<td>3.2 Other glioma</td>
<td>0.4 0.4</td>
<td>0.6 0.6</td>
<td>1.0 1.0</td>
<td>1.5 1.0</td>
<td>1.5 1.0</td>
</tr>
<tr>
<td>3.3 Ependymoma</td>
<td>0.2 -</td>
<td>0.2 0.2</td>
<td>0.3 0.2</td>
<td>0.2 0.2</td>
<td>0.3 0.3</td>
</tr>
<tr>
<td>3.4 Medulloblastoma and other PNET</td>
<td>0.3 0.2</td>
<td>0.3 0.2</td>
<td>0.3 0.2</td>
<td>0.2 0.2</td>
<td>0.2 -</td>
</tr>
<tr>
<td>3.4.1 Medulloblastoma</td>
<td>0.2 0.1</td>
<td>- -</td>
<td>0.2 -</td>
<td>- -</td>
<td>- -</td>
</tr>
<tr>
<td>3.4.2 Supratentorial PNET</td>
<td>- -</td>
<td>0.2 -</td>
<td>0.2 -</td>
<td>- -</td>
<td>- -</td>
</tr>
<tr>
<td>3.5 Other specified intracranial and intraspinal neoplasms</td>
<td>- -</td>
<td>- -</td>
<td>- -</td>
<td>- -</td>
<td>- -</td>
</tr>
<tr>
<td>3.6 Unspecified intracranial and intraspinal neoplasms</td>
<td>- -</td>
<td>- -</td>
<td>- -</td>
<td>- -</td>
<td>- -</td>
</tr>
<tr>
<td>4. OSSEOUS &amp; CHONDROMATOUS NEOPLASMS</td>
<td>2.1 1.3</td>
<td>1.3 0.9</td>
<td>0.9 0.8</td>
<td>0.9 0.6</td>
<td>0.8 0.8</td>
</tr>
<tr>
<td>4.1 Osteosarcoma</td>
<td>1.1 0.6</td>
<td>0.4 0.3</td>
<td>0.3 0.3</td>
<td>0.2 -</td>
<td>- 0.2</td>
</tr>
<tr>
<td>4.2 Chondrosarcoma</td>
<td>- -</td>
<td>0.2 0.1</td>
<td>0.2 0.2</td>
<td>0.3 0.2</td>
<td>0.4 0.3</td>
</tr>
<tr>
<td>4.3 Ewing tumor</td>
<td>0.8 0.5</td>
<td>0.6 0.3</td>
<td>0.3 0.3</td>
<td>0.2 0.2</td>
<td>- 0.2</td>
</tr>
<tr>
<td>4.4 Other specified and unspecified bone tumors</td>
<td>- -</td>
<td>- -</td>
<td>0.2 -</td>
<td>0.2 -</td>
<td>0.2 0.2</td>
</tr>
<tr>
<td>5. SOFT TISSUE SARCOMAS</td>
<td>1.4 1.3</td>
<td>1.6 1.6</td>
<td>2.7 2.0</td>
<td>3.8 2.6</td>
<td>4.1 3.2</td>
</tr>
<tr>
<td>5.1 Fibromatous neoplasms</td>
<td>0.2 0.3</td>
<td>0.3 0.4</td>
<td>0.6 0.6</td>
<td>0.8 0.9</td>
<td>0.8 0.9</td>
</tr>
<tr>
<td>5.2 Rhabdomyosarcoma</td>
<td>- 0.4</td>
<td>0.3 0.4</td>
<td>- -</td>
<td>- -</td>
<td>- -</td>
</tr>
<tr>
<td>5.3 Other specified soft tissue sarcoma</td>
<td>0.8 0.8</td>
<td>1.3 1.0</td>
<td>2.0 1.2</td>
<td>2.9 1.6</td>
<td>3.2 2.2</td>
</tr>
<tr>
<td>5.3.1 Specified soft tissue sarcoma</td>
<td>0.5 0.6</td>
<td>0.8 0.8</td>
<td>1.7 0.9</td>
<td>2.4 1.3</td>
<td>2.7 1.7</td>
</tr>
<tr>
<td>5.3.1.1 Specified (excluding Kaposi sarcoma)</td>
<td>0.5 0.6</td>
<td>0.7 0.8</td>
<td>1.1 0.9</td>
<td>1.4 1.3</td>
<td>1.7 1.7</td>
</tr>
<tr>
<td>5.3.1.2 Kaposi sarcoma</td>
<td>- -</td>
<td>0.1 -</td>
<td>0.6 -</td>
<td>1.1 -</td>
<td>1.0 -</td>
</tr>
<tr>
<td>5.3.2 Unspecified soft tissue sarcoma</td>
<td>0.3 0.2</td>
<td>0.4 0.2</td>
<td>0.3 0.3</td>
<td>0.4 0.3</td>
<td>0.5 0.5</td>
</tr>
<tr>
<td>6. GERM CELL AND TROPHOBLASTIC NEOPLASMS</td>
<td>5.4 1.1</td>
<td>13.4 1.1</td>
<td>18.4 1.0</td>
<td>17.0 0.7</td>
<td>13.7 0.6</td>
</tr>
<tr>
<td>6.1 Germ cell and trophoblastic neoplasms of gonads</td>
<td>4.8 0.9</td>
<td>12.6 0.8</td>
<td>18.0 0.7</td>
<td>16.6 0.3</td>
<td>13.5 0.4</td>
</tr>
<tr>
<td>6.2 Germ cell and trophoblastic neoplasms of nongonal sites</td>
<td>0.6 0.2</td>
<td>0.7 0.3</td>
<td>0.4 0.3</td>
<td>0.4 0.3</td>
<td>0.2 0.3</td>
</tr>
<tr>
<td>6.2.1 Intracranial sites</td>
<td>0.4 -</td>
<td>0.3 -</td>
<td>- -</td>
<td>- -</td>
<td>- -</td>
</tr>
<tr>
<td>6.2.2 Other nongonal sites</td>
<td>0.3 -</td>
<td>0.4 0.3</td>
<td>0.4 0.3</td>
<td>0.3 0.4</td>
<td>0.2 0.3</td>
</tr>
</tbody>
</table>

Rates are per 100,000.

* SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose–Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

* Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

* Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>7.1 Melanoma</td>
<td>1.1</td>
<td>1.5</td>
<td>2.5</td>
<td>6.5</td>
<td>5.4</td>
</tr>
<tr>
<td>7.2 Skin carcinomas</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8. CARCINOMAS (excluding skin)</td>
<td>2.6</td>
<td>7.9</td>
<td>6.1</td>
<td>18.9</td>
<td>11.2</td>
</tr>
<tr>
<td>8.1 Thyroid carcinoma</td>
<td>1.0</td>
<td>5.6</td>
<td>2.1</td>
<td>11.7</td>
<td>3.6</td>
</tr>
<tr>
<td>8.2 Other carcinoma of head and neck</td>
<td>0.4</td>
<td>0.5</td>
<td>0.8</td>
<td>0.7</td>
<td>1.0</td>
</tr>
<tr>
<td>8.2.1 Nasopharyngeal carcinoma</td>
<td>0.2</td>
<td>-</td>
<td>0.1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8.2.2 Other sites in lip, oral cavity and pharynx</td>
<td>0.3</td>
<td>0.4</td>
<td>0.6</td>
<td>0.5</td>
<td>0.8</td>
</tr>
<tr>
<td>8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8.3 Carcinoma of trachea, bronchus, and lung</td>
<td>-</td>
<td>0.1</td>
<td>0.3</td>
<td>0.4</td>
<td>0.5</td>
</tr>
<tr>
<td>8.4 Carcinoma of breast</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1.4</td>
</tr>
<tr>
<td>8.5 Carcinoma of genitourinary tract</td>
<td>0.3</td>
<td>0.7</td>
<td>0.8</td>
<td>2.9</td>
<td>1.9</td>
</tr>
<tr>
<td>8.5.1 Carcinoma of kidney</td>
<td>0.2</td>
<td>0.2</td>
<td>0.4</td>
<td>0.5</td>
<td>1.2</td>
</tr>
<tr>
<td>8.5.2 Carcinoma of bladder</td>
<td>-</td>
<td>-</td>
<td>0.3</td>
<td>-</td>
<td>0.5</td>
</tr>
<tr>
<td>8.5.3 Carcinoma of gonads</td>
<td>-</td>
<td>0.3</td>
<td>-</td>
<td>0.8</td>
<td>-</td>
</tr>
<tr>
<td>8.5.4 Carcinoma of cervix and uterus</td>
<td>-</td>
<td>0.1</td>
<td>-</td>
<td>1.5</td>
<td>-</td>
</tr>
<tr>
<td>8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
</tr>
<tr>
<td>8.6 Carcinoma of gastrointestinal tract</td>
<td>0.7</td>
<td>0.8</td>
<td>1.9</td>
<td>1.7</td>
<td>3.9</td>
</tr>
<tr>
<td>8.6.1 Carcinoma of colon and rectum</td>
<td>0.5</td>
<td>0.6</td>
<td>1.3</td>
<td>1.1</td>
<td>2.7</td>
</tr>
<tr>
<td>8.6.2 Carcinoma of stomach</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
<td>0.2</td>
<td>0.4</td>
</tr>
<tr>
<td>8.6.3 Carcinoma of liver and intrahepatic bile ducts</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
<td>0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>8.6.4 Carcinoma of pancreas</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.3</td>
</tr>
<tr>
<td>8.7 Carcinoma of other and ill-defined sites, NOS</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
<td>0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>8.7.1 Adrenocortical carcinoma</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8.7.2 Carcinoma of other and ill-defined sites, NOS</td>
<td>-</td>
<td>-</td>
<td>0.1</td>
<td>0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS</td>
<td>0.3</td>
<td>0.4</td>
<td>0.3</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>9.1 Other pediatric and embryonal tumors, NOS</td>
<td>0.1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>9.1.1 Wilms tumor</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>9.1.2 Neuroblastoma</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>9.1.3 Other pediatric and embryonal tumors, NOS</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>9.2 Other specified neoplasms, NOS</td>
<td>0.1</td>
<td>0.3</td>
<td>0.3</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>9.2.1 Paraganglioma and glomus tumors</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>9.2.2 Other specified gonadal tumors</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
<td>-</td>
</tr>
<tr>
<td>9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>9.2.4 Other specified neoplasms, NOS</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
<td>0.2</td>
<td>0.5</td>
</tr>
<tr>
<td>10. UNSPECIFIED MALIGNANT NEOPLASMS</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
<td>0.3</td>
<td>0.2</td>
</tr>
</tbody>
</table>

Rates are per 100,000.

a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose–Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RC).

b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

c Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O-3.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
### Table 32.6
Age-Specific SEER Incidence*, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adultsb
Black, 2010-2014

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites Combined</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>1. LEUKEMIAS</td>
<td>15.5</td>
<td>14.6</td>
<td>21.6</td>
<td>22.4</td>
<td>31.6</td>
</tr>
<tr>
<td>1.1 Acute lymphoid leukemia</td>
<td>2.2</td>
<td>1.5</td>
<td>1.8</td>
<td>2.1</td>
<td>2.2</td>
</tr>
<tr>
<td>1.2 Acute myeloid leukemia</td>
<td>1.1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1.3 Chronic myeloid leukemia</td>
<td>-</td>
<td>-</td>
<td>0.8</td>
<td>1.1</td>
<td>-</td>
</tr>
<tr>
<td>1.4 Other and unspecified leukaemias</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2. LYMPHOMAS</td>
<td>4.9</td>
<td>2.9</td>
<td>6.7</td>
<td>5.2</td>
<td>8.8</td>
</tr>
<tr>
<td>2.1 Non-Hodgkin Lymphoma</td>
<td>2.4</td>
<td>0.9</td>
<td>3.6</td>
<td>1.7</td>
<td>4.4</td>
</tr>
<tr>
<td>2.2 Hodgkin Lymphoma</td>
<td>2.5</td>
<td>1.9</td>
<td>3.1</td>
<td>3.5</td>
<td>4.4</td>
</tr>
<tr>
<td>3. CNS, INTRACRANIAL, INTRASPINAL</td>
<td>1.9</td>
<td>1.7</td>
<td>1.3</td>
<td>2.2</td>
<td>1.4</td>
</tr>
<tr>
<td>3.1 Astrocytoma</td>
<td>1.0</td>
<td>1.1</td>
<td>0.8</td>
<td>-</td>
<td>1.0</td>
</tr>
<tr>
<td>3.1.1 Specified low-grade astrocytic tumors</td>
<td>-</td>
<td>0.7</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.1.2 Glioblastoma and anaplastic astrocytoma</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.1.3 Astrocytoma, NOS</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.2 Other glioma</td>
<td>1.4</td>
<td>-</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.3 Ependymoma</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.4 Medulloblastoma and other PNET</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.4.1 Medulloblastoma</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.4.2 Supratentorial PNET</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.5 Other specified intracranial and intraspinal neoplasms</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.6 Unspecified intracranial and intraspinal neoplasms</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4. OSSEOUS &amp; CHONDROMATOUS NEOPLASMS</td>
<td>1.4</td>
<td>1.0</td>
<td>0.8</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4.1 Osteosarcoma</td>
<td>0.8</td>
<td>0.8</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4.2 Chondrosarcoma</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4.3 Ewing tumor</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4.4 Other specified and unspecified bone tumors</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5. SOFT TISSUE SARCOMAS</td>
<td>1.6</td>
<td>1.2</td>
<td>5.3</td>
<td>1.9</td>
<td>6.3</td>
</tr>
<tr>
<td>5.1 Fibromatous neoplasms</td>
<td>-</td>
<td>-</td>
<td>0.7</td>
<td>0.7</td>
<td>1.5</td>
</tr>
<tr>
<td>5.2 Rhabdomyosarcoma</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5.3 Other specified soft tissue sarcoma</td>
<td>-</td>
<td>-</td>
<td>4.2</td>
<td>1.0</td>
<td>4.8</td>
</tr>
<tr>
<td>5.3.1 Specified soft tissue sarcoma</td>
<td>-</td>
<td>-</td>
<td>3.7</td>
<td>0.7</td>
<td>4.5</td>
</tr>
<tr>
<td>5.3.1.1 Specified (excluding Kaposi sarcoma)</td>
<td>-</td>
<td>-</td>
<td>1.1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5.3.1.2 Kaposi sarcoma</td>
<td>-</td>
<td>2.6</td>
<td>-</td>
<td>4.0</td>
<td>-</td>
</tr>
<tr>
<td>5.3.2 Unspecified soft tissue sarcoma</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6. GERM CELL AND TROPHOBLASTIC NEOPLASMS</td>
<td>0.7</td>
<td>1.3</td>
<td>1.8</td>
<td>1.2</td>
<td>2.5</td>
</tr>
<tr>
<td>6.1 Germ cell and trophoblastic neoplasms of gonads</td>
<td>-</td>
<td>1.0</td>
<td>1.7</td>
<td>0.8</td>
<td>2.4</td>
</tr>
<tr>
<td>6.2 Germ cell and trophoblastic neoplasms of nongonadal sites</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6.2.1 Intracranial sites</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6.2.2 Other nongonadal sites</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Rates are per 100,000.

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
Table 32.6 - continued
Age-Specific SEER Incidence*, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adultsb
Black, 2010-2014

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>7. MELANOMA AND SKIN CARCINOMAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.1 Melanoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.2 Skin carcinomas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. CARCINOMAS (excluding skin)</td>
<td>2.1</td>
<td>4.2</td>
<td>3.2</td>
<td>9.4</td>
<td>9.0</td>
<td>33.8</td>
<td>18.5</td>
<td>72.0</td>
<td>38.8</td>
<td>129.7</td>
</tr>
<tr>
<td>8.1 Thyroid carcinoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2 Other carcinoma of head and neck</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.1 Nasopharyngeal carcinoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.2 Other sites in lip, oral cavity and pharynx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3 Carcinoma of trachea, bronchus, and lung</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.4 Carcinoma of breast</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5 Carcinoma of genitourinary tract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5.1 Carcinoma of kidney</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5.2 Carcinoma of bladder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5.3 Carcinoma of gonads</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5.4 Carcinoma of cervix and uterus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6 Carcinoma of gastrointestinal tract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6.1 Carcinoma of colon and rectum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6.2 Carcinoma of stomach</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6.3 Carcinoma of liver and intrahepatic bile ducts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6.4 Carcinoma of pancreas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.7 Carcinoma of other and ill-defined sites, NOS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.7.1 Adrenocortical carcinoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.7.2 Carcinoma of other and ill-defined sites, NOS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS</td>
<td>0.7</td>
<td></td>
<td>0.9</td>
<td></td>
<td>1.3</td>
<td></td>
<td>2.5</td>
<td></td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>9.1 Other pediatric and embryonal tumors, NOS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1.1 Wilms tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1.2 Neuroblastoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1.3 Other pediatric and embryonal tumors, NOS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.2 Other specified neoplasms, NOS</td>
<td>0.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.2</td>
<td></td>
<td>2.5</td>
<td></td>
</tr>
<tr>
<td>9.2.1 Paraganglioma and glomus tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.2.2 Other specified gonadal tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.2.4 Other specified neoplasms, NOSc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. UNSPECIFIED MALIGNANT NEOPLASMS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Rates are per 100,000.

a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/KB).

b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

c Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O 3.

d Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
### Table 32.7
**Age-Adjusted SEER Incidence**, by Year and Sex
*By Adapted Classification Scheme for Tumors of Adolescents and Young Adults*

#### All Races, Ages 15-19

<table>
<thead>
<tr>
<th></th>
<th>1975-2014</th>
<th></th>
<th></th>
<th>2005-2014</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Rate</td>
<td>AAPC</td>
<td>No.</td>
<td>Rate</td>
<td>AAPC</td>
</tr>
<tr>
<td><strong>Both Sexes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>15,352</td>
<td>20.8</td>
<td>0.6*</td>
<td>4,515</td>
<td>22.8</td>
<td>0.6*</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>1,813</td>
<td>2.5</td>
<td>0.7*</td>
<td>528</td>
<td>2.7</td>
<td>0.7*</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>3,778</td>
<td>5.1</td>
<td>0.1</td>
<td>1,031</td>
<td>5.2</td>
<td>0.1</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>1,504</td>
<td>2.0</td>
<td>0.6*</td>
<td>438</td>
<td>2.2</td>
<td>0.6*</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>1,182</td>
<td>1.6</td>
<td>0.5</td>
<td>336</td>
<td>1.7</td>
<td>0.5</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>1,097</td>
<td>1.5</td>
<td>0.1</td>
<td>300</td>
<td>1.5</td>
<td>0.1</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>1,846</td>
<td>2.5</td>
<td>0.8*</td>
<td>540</td>
<td>2.7</td>
<td>0.8*</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>1,117</td>
<td>1.5</td>
<td>0.1</td>
<td>304</td>
<td>1.5</td>
<td>0.1</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>2,710</td>
<td>3.7</td>
<td>2.0*</td>
<td>954</td>
<td>4.8</td>
<td>6.3*</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>248</td>
<td>0.3</td>
<td>0.7</td>
<td>79</td>
<td>0.4</td>
<td>0.7</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>57</td>
<td>0.1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>1975-2014</th>
<th></th>
<th></th>
<th>2005-2014</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Rate</td>
<td>AAPC</td>
<td>No.</td>
<td>Rate</td>
<td>AAPC</td>
</tr>
<tr>
<td><strong>Males</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>8,046</td>
<td>21.3</td>
<td>0.7*</td>
<td>2,350</td>
<td>23.1</td>
<td>0.7*</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>1,078</td>
<td>2.9</td>
<td>0.4</td>
<td>296</td>
<td>2.9</td>
<td>0.4</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>2,037</td>
<td>5.4</td>
<td>0.3</td>
<td>579</td>
<td>5.7</td>
<td>0.3</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>860</td>
<td>2.3</td>
<td>0.4</td>
<td>239</td>
<td>2.3</td>
<td>0.4</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>776</td>
<td>2.1</td>
<td>0.7*</td>
<td>224</td>
<td>2.2</td>
<td>0.7*</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>581</td>
<td>1.5</td>
<td>0.2</td>
<td>155</td>
<td>1.5</td>
<td>0.2</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>1,361</td>
<td>3.6</td>
<td>1.1*</td>
<td>421</td>
<td>4.1</td>
<td>1.1*</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>447</td>
<td>1.2</td>
<td>0.9</td>
<td>128</td>
<td>1.3</td>
<td>0.9</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>768</td>
<td>2.0</td>
<td>1.5*</td>
<td>267</td>
<td>2.6</td>
<td>1.5*</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>113</td>
<td>0.3</td>
<td>-</td>
<td>39</td>
<td>0.4</td>
<td>-</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>25</td>
<td>0.1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>1975-2014</th>
<th></th>
<th></th>
<th>2005-2014</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Rate</td>
<td>AAPC</td>
<td>No.</td>
<td>Rate</td>
<td>AAPC</td>
</tr>
<tr>
<td><strong>Females</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>7,306</td>
<td>20.2</td>
<td>0.6*</td>
<td>2,165</td>
<td>22.4</td>
<td>0.6*</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>735</td>
<td>2.0</td>
<td>1.2*</td>
<td>232</td>
<td>2.4</td>
<td>1.2*</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>1,741</td>
<td>4.8</td>
<td>-0.1</td>
<td>452</td>
<td>4.7</td>
<td>-0.1</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>644</td>
<td>1.8</td>
<td>0.8*</td>
<td>199</td>
<td>2.1</td>
<td>0.8*</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>406</td>
<td>1.1</td>
<td>0.2</td>
<td>112</td>
<td>1.2</td>
<td>0.2</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>516</td>
<td>1.4</td>
<td>0.2</td>
<td>145</td>
<td>1.5</td>
<td>0.2</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>485</td>
<td>1.3</td>
<td>-0.3</td>
<td>119</td>
<td>1.2</td>
<td>-0.3</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>670</td>
<td>1.9</td>
<td>0.4</td>
<td>176</td>
<td>1.8</td>
<td>0.4</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>1,942</td>
<td>5.4</td>
<td>2.2*</td>
<td>687</td>
<td>7.1</td>
<td>7.9*</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>135</td>
<td>0.4</td>
<td>-</td>
<td>40</td>
<td>0.4</td>
<td>-</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>32</td>
<td>0.1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2014.

Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

The AAPC is significantly different from zero (p<.05).
Table 32.8
Age-Adjusted SEER Incidence*, by Year and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults
All Races, Ages 20-24

<table>
<thead>
<tr>
<th>Both Sexes</th>
<th>1975-2014</th>
<th>2005-2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Rate</td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>26,170</td>
<td>34.5</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>1,683</td>
<td>2.2</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>5,434</td>
<td>7.2</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>1,723</td>
<td>2.3</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>695</td>
<td>0.9</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>1,585</td>
<td>2.1</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>4,077</td>
<td>5.4</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>3,266</td>
<td>4.3</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>1,585</td>
<td>2.1</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>165</td>
<td>0.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Males</th>
<th>1975-2014</th>
<th>2005-2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Rate</td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>12,850</td>
<td>33.4</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>963</td>
<td>2.5</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>2,918</td>
<td>7.6</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>963</td>
<td>2.5</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>410</td>
<td>1.1</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>948</td>
<td>2.5</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>3,641</td>
<td>9.5</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>1,112</td>
<td>2.9</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>1,720</td>
<td>4.5</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>113</td>
<td>0.3</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>62</td>
<td>0.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Females</th>
<th>1975-2014</th>
<th>2005-2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Rate</td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>13,320</td>
<td>35.7</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>720</td>
<td>1.9</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>2,516</td>
<td>6.7</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>760</td>
<td>2.0</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>285</td>
<td>0.8</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>637</td>
<td>1.7</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>436</td>
<td>1.2</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>2,154</td>
<td>5.8</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>5,537</td>
<td>14.8</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>172</td>
<td>0.5</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>103</td>
<td>0.3</td>
</tr>
</tbody>
</table>

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).

a Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 105:7; 2015-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

c The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2014.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero (p<0.05).
### Table 32.9

Age-Adjusted SEER Incidence*, by Year and Sex

By Adapted Classification Scheme for Tumors of Adolescents and Young Adults

All Races, Ages 25-29

<table>
<thead>
<tr>
<th>Both Sexes</th>
<th>1975-2014</th>
<th>2005-2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Rate</td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>44,474</td>
<td>56.1</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>1,911</td>
<td>2.4</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>6,571</td>
<td>8.3</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>2,314</td>
<td>2.9</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>549</td>
<td>0.7</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>3,208</td>
<td>4.0</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>5,697</td>
<td>7.2</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>6,608</td>
<td>7.6</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>17,514</td>
<td>22.1</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>424</td>
<td>0.5</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>218</td>
<td>0.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Males</th>
<th>1975-2014</th>
<th>2005-2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Rate</td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>20,030</td>
<td>50.2</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>1,105</td>
<td>2.8</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>3,743</td>
<td>9.4</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>1,268</td>
<td>3.2</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>313</td>
<td>0.8</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>2,340</td>
<td>5.9</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>5,267</td>
<td>13.2</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>2,149</td>
<td>5.4</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>3,594</td>
<td>9.0</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>157</td>
<td>0.4</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>94</td>
<td>0.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Females</th>
<th>1975-2014</th>
<th>2005-2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Rate</td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>24,444</td>
<td>62.0</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>806</td>
<td>2.0</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>2,828</td>
<td>7.2</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>1,046</td>
<td>2.7</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>236</td>
<td>0.6</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>868</td>
<td>2.2</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>430</td>
<td>1.1</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>3,919</td>
<td>9.9</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>13,920</td>
<td>35.3</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>267</td>
<td>0.7</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>124</td>
<td>0.3</td>
</tr>
</tbody>
</table>

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

* Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

c The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2014.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero (p<.05).
Table 32.10

Age-Adjusted SEER Incidence*, by Year and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adultsb
All Races, Ages 30-34

<table>
<thead>
<tr>
<th>Both Sexes</th>
<th>1975-2014</th>
<th>2005-2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>Rate</td>
<td>AAPC</td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>68,312</td>
<td>86.2</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>2,280</td>
<td>2.9</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>7,359</td>
<td>9.3</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>2,687</td>
<td>3.4</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>502</td>
<td>0.6</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>5,291</td>
<td>6.7</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>5,706</td>
<td>7.2</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>8,704</td>
<td>11.0</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>34,668</td>
<td>43.7</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>764</td>
<td>1.0</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>350</td>
<td>0.4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Males</th>
<th>1975-2014</th>
<th>2005-2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>Rate</td>
<td>AAPC</td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>28,150</td>
<td>71.0</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>1,314</td>
<td>3.3</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>4,536</td>
<td>11.4</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>1,571</td>
<td>4.0</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>283</td>
<td>0.7</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>4,228</td>
<td>10.7</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>5,339</td>
<td>13.5</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>3,450</td>
<td>8.7</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>7,006</td>
<td>17.7</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>296</td>
<td>0.7</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>127</td>
<td>0.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Females</th>
<th>1975-2014</th>
<th>2005-2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>Rate</td>
<td>AAPC</td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>40,162</td>
<td>101.4</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>966</td>
<td>2.4</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>2,823</td>
<td>7.1</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>1,116</td>
<td>2.8</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>219</td>
<td>0.6</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>1,063</td>
<td>2.7</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>367</td>
<td>0.9</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>5,254</td>
<td>13.3</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>27,662</td>
<td>69.8</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>468</td>
<td>1.2</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>223</td>
<td>0.6</td>
</tr>
</tbody>
</table>

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).

* Rates are from the SEER 9 areas (San Francisco, California, Cleveland, Iowa, New Mexico, Seattle, Utah, Atlanta).

b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

c The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2014.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero (p<.05).
### Table 32.11

**Age-Adjusted SEER Incidence*, by Year and Sex**

*By Adapted Classification Scheme for Tumors of Adolescents and Young Adults*

**All Races, Ages 35-39**

<table>
<thead>
<tr>
<th></th>
<th>1975-2014</th>
<th></th>
<th>2005-2014</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Rate</td>
<td>AAPC</td>
<td>No.</td>
</tr>
<tr>
<td><strong>Both Sexes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>100,203</td>
<td>133.7</td>
<td>0.8*</td>
<td>27,924</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>2,855</td>
<td>3.8</td>
<td>0.6</td>
<td>834</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>8,327</td>
<td>11.1</td>
<td>1.3*</td>
<td>2,136</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>2,961</td>
<td>3.9</td>
<td>-0.2</td>
<td>747</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>506</td>
<td>0.7</td>
<td>1.4*</td>
<td>160</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>6,190</td>
<td>8.3</td>
<td>0.8</td>
<td>948</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>4,449</td>
<td>5.9</td>
<td>1.6*</td>
<td>1,271</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>10,891</td>
<td>14.5</td>
<td>1.5*</td>
<td>3,137</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>4,449</td>
<td>5.9</td>
<td>1.6*</td>
<td>1,271</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>1,344</td>
<td>1.8</td>
<td>1.4*</td>
<td>432</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>515</td>
<td>0.7</td>
<td>-0.2</td>
<td>119</td>
</tr>
</tbody>
</table>

**Males**

<table>
<thead>
<tr>
<th></th>
<th>1975-2014</th>
<th></th>
<th>2005-2014</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Rate</td>
<td>AAPC</td>
<td>No.</td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>37,383</td>
<td>100.1</td>
<td>0.5</td>
<td>9,521</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>1,648</td>
<td>4.4</td>
<td>0.2</td>
<td>469</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>5,380</td>
<td>14.4</td>
<td>1.4*</td>
<td>1,263</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>1,738</td>
<td>4.7</td>
<td>-0.1</td>
<td>447</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>287</td>
<td>0.8</td>
<td>0.6</td>
<td>87</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>4,829</td>
<td>12.9</td>
<td>2.0</td>
<td>592</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>4,218</td>
<td>11.3</td>
<td>1.7*</td>
<td>1,203</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>4,712</td>
<td>12.6</td>
<td>0.6</td>
<td>1,235</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>13,822</td>
<td>37.0</td>
<td>0.3</td>
<td>4,012</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>543</td>
<td>1.5</td>
<td>1.1*</td>
<td>171</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>206</td>
<td>0.6</td>
<td>-0.7</td>
<td>42</td>
</tr>
</tbody>
</table>

**Females**

<table>
<thead>
<tr>
<th></th>
<th>1975-2014</th>
<th></th>
<th>2005-2014</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Rate</td>
<td>AAPC</td>
<td>No.</td>
</tr>
<tr>
<td>All Sites Combined</td>
<td>62,820</td>
<td>167.0</td>
<td>0.8*</td>
<td>18,403</td>
</tr>
<tr>
<td>1. Leukemias</td>
<td>1,207</td>
<td>3.2</td>
<td>1.1</td>
<td>365</td>
</tr>
<tr>
<td>2. Lymphomas</td>
<td>2,947</td>
<td>7.8</td>
<td>1.3*</td>
<td>873</td>
</tr>
<tr>
<td>3. CNS, intracranial, intraspinal</td>
<td>1,223</td>
<td>3.3</td>
<td>-0.3</td>
<td>300</td>
</tr>
<tr>
<td>4. Osseous &amp; chondromatous neoplasms</td>
<td>219</td>
<td>0.6</td>
<td>-</td>
<td>73</td>
</tr>
<tr>
<td>5. Soft tissue sarcomas</td>
<td>1,361</td>
<td>3.6</td>
<td>-0.5</td>
<td>356</td>
</tr>
<tr>
<td>6. Germ cell and trophoblastic neoplasms</td>
<td>231</td>
<td>0.6</td>
<td>0.3</td>
<td>68</td>
</tr>
<tr>
<td>7. Melanoma and skin carcinomas</td>
<td>6,179</td>
<td>16.4</td>
<td>1.8</td>
<td>1,902</td>
</tr>
<tr>
<td>8. Carcinomas (excluding skin)</td>
<td>48,343</td>
<td>128.5</td>
<td>0.6*</td>
<td>14,128</td>
</tr>
<tr>
<td>9. Miscellaneous specified neoplasms, NOS</td>
<td>801</td>
<td>2.1</td>
<td>1.6*</td>
<td>261</td>
</tr>
<tr>
<td>10. Unspecified malignant neoplasms</td>
<td>309</td>
<td>0.8</td>
<td>-0.2</td>
<td>77</td>
</tr>
</tbody>
</table>

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).

* Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

c The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2014.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero (p<.05).
### Table 32.12
SEER Incidence<sup>a</sup> and U.S. Mortality<sup>b</sup> Rate Comparison by Race/Ethnicity, 2010-2014
Ages 15-19

<table>
<thead>
<tr>
<th>All Malignant Cancers</th>
<th>Incidence</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All</td>
<td>White</td>
</tr>
<tr>
<td>Males</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All Races</td>
<td>White</td>
</tr>
<tr>
<td></td>
<td>23.4</td>
<td>25.4</td>
</tr>
<tr>
<td>Leukemia</td>
<td>3.8</td>
<td>4.2</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>5.5</td>
<td>5.7</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>3.1</td>
<td>3.3</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>2.5</td>
<td>2.4</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>2.5</td>
<td>2.7</td>
</tr>
<tr>
<td>Bones and Joints</td>
<td>1.7</td>
<td>1.8</td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>1.1</td>
<td>1.2</td>
</tr>
<tr>
<td>Skin excluding Basal and Squamous</td>
<td>1.0</td>
<td>1.2</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Male Genital System</td>
<td>4.0</td>
<td>5.0</td>
</tr>
<tr>
<td>Digestive System</td>
<td>0.8</td>
<td>0.8</td>
</tr>
</tbody>
</table>

| Females               |           |           |       |               |               |     |       |       |               |               |
|                       | All Races | White     | Black | API<sup>c</sup> | Hispanic<sup>d</sup> |     |       |       |               |               |
|                       | 21.6      | 23.4      | 14.6  | 17.2          | 19.1          | 2.4 | 2.4   | 2.4   | 2.3          | 2.4          |
| Leukemia              | 2.6       | 2.8       | 1.5   | 2.8           | 3.3           | 0.6 | 0.6   | 0.5   | 0.6          | 0.9          |
| Lymphoma              | 4.3       | 4.7       | 2.9   | 3.4           | 3.3           | 0.1 | 0.1   | 0.2   | -            | -            |
| Hodgkin Lymphoma      | 3.0       | 3.4       | 1.9   | 1.7           | 2.2           | 0.0 | -     | -     | -            | -            |
| Non-Hodgkin Lymphoma  | 1.2       | 1.3       | 0.9   | 1.7           | 1.1           | 0.1 | 0.1   | -     | -            | -            |
| Brain and Other Nervous System | 2.1 | 2.2 | 1.6 | 1.4 | 1.4 | 0.4 | 0.4 | 0.6 | - | 0.4 |
| Bones and Joints      | 1.0       | 1.1       | 1.1   | -             | 0.7           | 0.4 | 0.4   | 0.3   | -            | 0.4          |
| Soft Tissue including Heart | 1.1 | 1.1 | 0.8 | - | 1.2 | 0.3 | 0.3 | 0.3 | - | 0.2 |
| Skin excluding Basal and Squamous | 1.3 | 1.6 | - | - | 0.4 | 0.0 | 0.0 | - | - |
| Respiratory System    | 0.2       | 0.3       | -     | -             | -             | 0.0 | -     | -     | -            | -            |
| Breast                | 0.2       | -         | -     | -             | -             | -   | -     | -     | -            | -            |
| Female Genital System | 1.9       | 1.9       | 1.9   | 1.5           | 2.2           | 0.1 | 0.1   | -     | -            | -            |
| Digestive System      | 0.9       | 0.9       | 0.9   | -             | 0.7           | 0.1 | 0.1   | 0.1   | -            |

---

<sup>a</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>b</sup> US Mortality Files, National Center for Health Statistics, CDC.

<sup>c</sup> Asian/Pacific Islander

<sup>d</sup> Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

---

Rates are per 100,000.

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
Table 32.13
SEER Incidence<sup>a</sup> and U.S. Mortality<sup>b</sup> Rate Comparison by Race/Ethnicity, 2010-2014
Ages 20-24

<table>
<thead>
<tr>
<th></th>
<th>Incidence</th>
<th></th>
<th></th>
<th>Mortality</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Races</td>
<td>White</td>
<td>Black</td>
<td>API&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Hispanic&lt;sup&gt;d&lt;/sup&gt;</td>
<td>All Races</td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>35.1</td>
<td>38.7</td>
<td>21.6</td>
<td>22.0</td>
<td>33.5</td>
<td>5.0</td>
</tr>
<tr>
<td>Leukemia</td>
<td>3.1</td>
<td>3.4</td>
<td>1.8</td>
<td>2.8</td>
<td>4.4</td>
<td>1.1</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>7.1</td>
<td>7.3</td>
<td>6.7</td>
<td>5.2</td>
<td>5.9</td>
<td>0.5</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>4.0</td>
<td>4.3</td>
<td>3.1</td>
<td>2.9</td>
<td>3.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>3.1</td>
<td>3.0</td>
<td>3.6</td>
<td>2.3</td>
<td>2.8</td>
<td>0.3</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>2.4</td>
<td>2.7</td>
<td>1.3</td>
<td>1.6</td>
<td>1.4</td>
<td>0.6</td>
</tr>
<tr>
<td>Bones and Joints</td>
<td>1.0</td>
<td>1.1</td>
<td>0.7</td>
<td>--</td>
<td>1.0</td>
<td>0.6</td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>1.4</td>
<td>1.3</td>
<td>1.7</td>
<td>1.2</td>
<td>1.3</td>
<td>0.4</td>
</tr>
<tr>
<td>Skin excluding Basal and Squamous</td>
<td>2.2</td>
<td>2.6</td>
<td>--</td>
<td>--</td>
<td>0.6</td>
<td>0.1</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>0.7</td>
<td>0.7</td>
<td>--</td>
<td>1.2</td>
<td>0.8</td>
<td>0.1</td>
</tr>
<tr>
<td>Male Genital System</td>
<td>10.6</td>
<td>12.9</td>
<td>2.0</td>
<td>4.0</td>
<td>13.6</td>
<td>0.4</td>
</tr>
<tr>
<td>Digestive System</td>
<td>2.0</td>
<td>2.1</td>
<td>1.7</td>
<td>1.2</td>
<td>1.8</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All Races</td>
<td>White</td>
<td>Black</td>
<td>API&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Hispanic&lt;sup&gt;d&lt;/sup&gt;</td>
<td>All Races</td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>37.1</td>
<td>41.1</td>
<td>22.4</td>
<td>25.7</td>
<td>29.6</td>
<td>3.5</td>
</tr>
<tr>
<td>Leukemia</td>
<td>2.3</td>
<td>2.4</td>
<td>2.1</td>
<td>--</td>
<td>2.7</td>
<td>0.8</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>6.4</td>
<td>6.7</td>
<td>5.2</td>
<td>4.8</td>
<td>4.6</td>
<td>0.3</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>4.3</td>
<td>4.6</td>
<td>3.5</td>
<td>2.5</td>
<td>3.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>2.1</td>
<td>2.1</td>
<td>1.7</td>
<td>2.3</td>
<td>1.6</td>
<td>0.2</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>2.0</td>
<td>2.2</td>
<td>1.2</td>
<td>1.8</td>
<td>1.3</td>
<td>0.5</td>
</tr>
<tr>
<td>Bones and Joints</td>
<td>0.7</td>
<td>0.7</td>
<td>--</td>
<td>--</td>
<td>0.7</td>
<td>0.3</td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>1.2</td>
<td>1.2</td>
<td>1.3</td>
<td>--</td>
<td>1.1</td>
<td>0.3</td>
</tr>
<tr>
<td>Skin excluding Basal and Squamous</td>
<td>5.3</td>
<td>6.6</td>
<td>0.7</td>
<td>--</td>
<td>1.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>0.5</td>
<td>0.6</td>
<td>--</td>
<td>0.5</td>
<td>--</td>
<td>0.1</td>
</tr>
<tr>
<td>Breast</td>
<td>1.5</td>
<td>1.5</td>
<td>1.8</td>
<td>1.0</td>
<td>1.3</td>
<td>0.1</td>
</tr>
<tr>
<td>Female Genital System</td>
<td>3.7</td>
<td>3.8</td>
<td>3.6</td>
<td>3.1</td>
<td>4.3</td>
<td>0.3</td>
</tr>
<tr>
<td>Digestive System</td>
<td>1.9</td>
<td>1.9</td>
<td>1.7</td>
<td>1.9</td>
<td>1.4</td>
<td>0.4</td>
</tr>
</tbody>
</table>

Rates are per 100,000.

<sup>a</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/NG).

<sup>b</sup> US Mortality Files, National Center for Health Statistics, CDC.

<sup>c</sup> Asian/Pacific Islander

<sup>d</sup> Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

-- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
Table 32.14
SEER Incidence<sup>a</sup> and U.S. Mortality<sup>b</sup> Rate Comparison by Race/Ethnicity, 2010-2014
Ages 25-29

<table>
<thead>
<tr>
<th>Males</th>
<th>Incidence</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Races</td>
<td>White</td>
</tr>
<tr>
<td></td>
<td>All Malignant Cancers</td>
<td>49.3</td>
</tr>
<tr>
<td>Leukemia</td>
<td>3.3</td>
<td>3.4</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>7.7</td>
<td>7.8</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>3.9</td>
<td>4.1</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>3.8</td>
<td>3.7</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>3.2</td>
<td>3.6</td>
</tr>
<tr>
<td>Bones and Joints</td>
<td>0.7</td>
<td>0.8</td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>1.6</td>
<td>1.6</td>
</tr>
<tr>
<td>Skin excluding Basal and Squamous</td>
<td>4.5</td>
<td>5.5</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>Male Genital System</td>
<td>15.1</td>
<td>18.2</td>
</tr>
<tr>
<td>Digestive System</td>
<td>4.2</td>
<td>4.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Females</th>
<th>Incidence</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Races</td>
<td>White</td>
</tr>
<tr>
<td></td>
<td>All Malignant Cancers</td>
<td>67.5</td>
</tr>
<tr>
<td>Leukemia</td>
<td>2.5</td>
<td>2.7</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>6.8</td>
<td>7.1</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>4.0</td>
<td>4.4</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>2.8</td>
<td>2.7</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>2.6</td>
<td>3.0</td>
</tr>
<tr>
<td>Bones and Joints</td>
<td>0.6</td>
<td>0.7</td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>Skin excluding Basal and Squamous</td>
<td>9.0</td>
<td>11.1</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>0.8</td>
<td>0.7</td>
</tr>
<tr>
<td>Breast</td>
<td>9.2</td>
<td>8.8</td>
</tr>
<tr>
<td>Female Genital System</td>
<td>9.7</td>
<td>10.0</td>
</tr>
<tr>
<td>Digestive System</td>
<td>4.0</td>
<td>4.0</td>
</tr>
</tbody>
</table>

Rates are per 100,000.
SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RO).
US Mortality Files, National Center for Health Statistics, CDC.
Asian/Pacific Islander
Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
### Table 32.15

SEER Incidence\(^a\) and U.S. Mortality\(^b\) Rate Comparison by Race/Ethnicity, 2010-2014

Ages 30-34

<table>
<thead>
<tr>
<th></th>
<th>Males</th>
<th></th>
<th>Females</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Races</td>
<td>Incidence</td>
<td>All Races</td>
<td>Mortality</td>
</tr>
<tr>
<td></td>
<td>Black</td>
<td>Hispanic</td>
<td>API(^c)</td>
<td>Hispanic</td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>67.1</td>
<td>51.0</td>
<td>43.5</td>
<td>50.4</td>
</tr>
<tr>
<td>Leukemia</td>
<td>3.9</td>
<td>2.6</td>
<td>3.4</td>
<td>4.2</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>9.2</td>
<td>11.3</td>
<td>6.0</td>
<td>6.5</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>3.7</td>
<td>4.2</td>
<td>1.8</td>
<td>2.3</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>5.5</td>
<td>7.1</td>
<td>4.3</td>
<td>4.2</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>4.0</td>
<td>2.4</td>
<td>2.6</td>
<td>3.0</td>
</tr>
<tr>
<td>Bones and Joints</td>
<td>0.7</td>
<td>-</td>
<td>-</td>
<td>0.8</td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>2.0</td>
<td>2.2</td>
<td>1.9</td>
<td>1.9</td>
</tr>
<tr>
<td>Skin excluding Basal and Squamous</td>
<td>7.6</td>
<td>1.7</td>
<td>1.0</td>
<td>1.6</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>1.8</td>
<td>2.9</td>
<td>1.3</td>
<td>1.6</td>
</tr>
<tr>
<td>Male Genital System</td>
<td>14.4</td>
<td>4.5</td>
<td>5.8</td>
<td>12.6</td>
</tr>
<tr>
<td>Digestive System</td>
<td>8.6</td>
<td>8.9</td>
<td>8.5</td>
<td>7.6</td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>115.2</td>
<td>93.9</td>
<td>85.9</td>
<td>91.9</td>
</tr>
<tr>
<td>Leukemia</td>
<td>3.1</td>
<td>2.8</td>
<td>2.8</td>
<td>3.2</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>7.1</td>
<td>8.2</td>
<td>4.8</td>
<td>5.4</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>3.2</td>
<td>3.3</td>
<td>1.8</td>
<td>2.1</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>3.9</td>
<td>4.9</td>
<td>2.9</td>
<td>3.3</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>2.8</td>
<td>1.8</td>
<td>1.5</td>
<td>2.1</td>
</tr>
<tr>
<td>Bones and Joints</td>
<td>0.4</td>
<td>-</td>
<td>-</td>
<td>0.5</td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>1.6</td>
<td>2.1</td>
<td>1.0</td>
<td>1.6</td>
</tr>
<tr>
<td>Skin excluding Basal and Squamous</td>
<td>12.9</td>
<td>1.3</td>
<td>1.0</td>
<td>3.0</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>1.4</td>
<td>1.3</td>
<td>1.2</td>
<td>1.1</td>
</tr>
<tr>
<td>Breast</td>
<td>27.3</td>
<td>33.3</td>
<td>24.8</td>
<td>20.7</td>
</tr>
<tr>
<td>Female Genital System</td>
<td>18.9</td>
<td>16.8</td>
<td>14.0</td>
<td>20.7</td>
</tr>
<tr>
<td>Digestive System</td>
<td>8.4</td>
<td>9.4</td>
<td>6.7</td>
<td>8.0</td>
</tr>
</tbody>
</table>

\(^a\) Rates are per 100,000.

\(^b\) SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

\(^c\) US Mortality Files, National Center for Health Statistics, CDC.

\(^d\) Asian/Pacific Islander

Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIIA and exclude cases from the Alaska Native Registry.

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
### Table 32.16

<table>
<thead>
<tr>
<th></th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Incidence</td>
<td>Mortality</td>
</tr>
<tr>
<td></td>
<td>All Races White Black APIc Hispanicd</td>
<td>All Races White Black APIc Hispanicd</td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>90.1 95.2 76.5 58.7 65.3</td>
<td>16.8 16.9 19.5 12.7 12.2</td>
</tr>
<tr>
<td>Leukemia</td>
<td>5.0 5.2 4.7 3.4 5.6</td>
<td>1.5 1.5 1.8 1.2 1.2</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>11.0 11.0 14.5 6.2 9.1</td>
<td>1.3 1.2 2.1 0.6 1.1</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>3.0 3.1 4.2 1.0 2.2</td>
<td>0.3 0.3 0.4 0.4 0.3</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>8.0 7.9 10.3 5.1 7.0</td>
<td>1.0 0.9 1.7 0.6 0.8</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>4.3 4.8 2.5 3.5 3.0</td>
<td>2.0 2.2 1.3 1.2 1.2</td>
</tr>
<tr>
<td>Bones and Joints</td>
<td>0.7 0.7 – – 0.6</td>
<td>0.3 0.3 0.3 – –</td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>10.7 12.9 1.5 1.7 1.8</td>
<td>1.0 1.3 – – 0.3</td>
</tr>
<tr>
<td>Skin excluding Basal and Squamous</td>
<td>3.6 3.6 3.7 3.2 2.6</td>
<td>1.6 1.6 1.9 1.4 0.9</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>2.6 3.2 1.7 2.4 2.3</td>
<td>1.3 1.4 0.8 0.8 0.7</td>
</tr>
<tr>
<td>Male Genital System</td>
<td>0.6 0.6 – – 0.5</td>
<td>0.1 0.1 0.2 – –</td>
</tr>
<tr>
<td>Digestive System</td>
<td>16.3 16.0 18.2 14.9 13.6</td>
<td>5.4 5.2 6.9 5.3 4.3</td>
</tr>
</tbody>
</table>

Rates are per 100,000.

a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

b US Mortality Files, National Center for Health Statistics, CDC.

c Asian/Pacific Islander

d Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
Table 32.17

SEER Incidence\(^a\) and U.S. Mortality\(^b\) Rates and Trends for the Top 5 Cancer Sites\(^c\) by Age
All Races, Both Sexes, 1975-2014

<table>
<thead>
<tr>
<th></th>
<th>Rates</th>
<th>Rate AAPC(^d)</th>
<th>Rate AAPC(^d)</th>
<th>Rate AAPC(^d)</th>
<th>Rate AAPC(^d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Malignant Cancers</td>
<td>20.8 0.6*</td>
<td>22.8 0.6*</td>
<td>4.0 -1.8*</td>
<td>3.0 -1.1</td>
<td></td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>3.5 -0.5*</td>
<td>3.2 -0.5*</td>
<td>0.2 -5.0*</td>
<td>0.1 -5.0*</td>
<td></td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>2.1 0.5</td>
<td>2.2 0.5</td>
<td>0.6 -0.4</td>
<td>0.5 2.6</td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>1.9 2.8*</td>
<td>2.8 8.5*</td>
<td>0.0 -</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>1.6 1.5*</td>
<td>2.0 1.5*</td>
<td>0.3 -3.7*</td>
<td>0.2 -6.3*</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>1.6 1.3*</td>
<td>1.9 1.3*</td>
<td>0.1 -5.2*</td>
<td>0.0 -2.6*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2005-2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ages 15-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>34.5 0.7*</td>
<td>38.5 0.7*</td>
<td>5.5 -1.4*</td>
<td>4.4 -1.2*</td>
<td></td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>4.9 0.2</td>
<td>4.8 -0.6*</td>
<td>0.4 -4.7*</td>
<td>0.2 -8.1*</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>4.5 1.1</td>
<td>5.2 -0.1*</td>
<td>0.3 -3.6*</td>
<td>0.2 1.0</td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>4.4 2.0*</td>
<td>6.0 2.0*</td>
<td>0.0 -</td>
<td>0.0 -</td>
<td></td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>4.2 0.6</td>
<td>4.6 -2.6*</td>
<td>0.2 -4.3*</td>
<td>0.1 -8.5*</td>
<td></td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>2.3 0.6*</td>
<td>2.5 0.6*</td>
<td>0.6 -0.8*</td>
<td>0.5 -0.8*</td>
<td></td>
</tr>
<tr>
<td>Ages 20-24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>56.1 0.7*</td>
<td>62.4 1.0*</td>
<td>8.2 -1.5*</td>
<td>6.6 -1.5*</td>
<td></td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>7.4 0.6</td>
<td>8.5 -1.8*</td>
<td>0.5 -2.9*</td>
<td>0.3 -2.9*</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>7.2 2.1*</td>
<td>10.8 3.8*</td>
<td>0.0 -</td>
<td>0.0 -</td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>6.5 1.2*</td>
<td>7.8 1.2*</td>
<td>0.3 -2.8*</td>
<td>0.2 0.8</td>
<td></td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>4.8 -0.1</td>
<td>4.7 -0.1*</td>
<td>0.5 -4.2*</td>
<td>0.2 -4.2*</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>4.2 0.4</td>
<td>4.5 2.6*</td>
<td>0.5 -2.2*</td>
<td>0.3 -2.2*</td>
<td></td>
</tr>
<tr>
<td>Ages 25-29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>86.2 0.9*</td>
<td>93.8 1.1*</td>
<td>14.3 -1.4*</td>
<td>11.0 -1.3*</td>
<td></td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>13.4 0.1</td>
<td>13.7 0.1</td>
<td>2.1 -2.0*</td>
<td>1.4 -2.6*</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>10.6 1.5*</td>
<td>11.8 0.1</td>
<td>0.9 -2.1*</td>
<td>0.6 -1.8*</td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>9.3 2.6*</td>
<td>15.2 3.3*</td>
<td>0.0 -1.3*</td>
<td>0.0 -1.3*</td>
<td></td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>6.6 1.9*</td>
<td>7.7 0.7*</td>
<td>0.3 -2.9*</td>
<td>0.2 -1.2*</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>5.7 -1.3*</td>
<td>4.6 -1.3*</td>
<td>0.9 -1.1*</td>
<td>0.6 -0.3</td>
<td></td>
</tr>
<tr>
<td>Ages 30-34</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>133.7 0.8*</td>
<td>141.1 0.8*</td>
<td>26.6 -1.5*</td>
<td>20.1 -1.0*</td>
<td></td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>31.7 0.4*</td>
<td>31.9 0.4*</td>
<td>5.0 -1.5*</td>
<td>3.5 -1.4</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>14.0 1.4*</td>
<td>15.2 0.3</td>
<td>1.3 -2.0*</td>
<td>0.8 -0.3</td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>11.4 3.7*</td>
<td>19.1 3.8*</td>
<td>0.1 -0.7</td>
<td>0.1 -0.7</td>
<td></td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>7.9 1.2</td>
<td>7.7 -3.1</td>
<td>1.5 -1.7*</td>
<td>0.8 -2.9*</td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>7.3 1.1*</td>
<td>9.0 2.5*</td>
<td>2.1 -0.5*</td>
<td>2.1 1.1*</td>
<td></td>
</tr>
</tbody>
</table>

Rates are per 100,000.

\(^a\) SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

\(^b\) US Mortality Files, National Center for Health Statistics, CDC.

\(^c\) Top 5 cancer sites selected based on 1975-2014 SEER 9 Incidence rates for the age group.

\(^d\) The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2014.

- Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

* The AAPC is significantly different from zero (p<.05).
### Table 32.18

SEER Incidence\(^a\) and U.S. Mortality\(^b\) Rates and Trends for the Top 5 Cancer Sites\(^c\) by Age

**All Races, Males, 1975-2014**

<table>
<thead>
<tr>
<th>Age Group</th>
<th>All Malignant Cancers</th>
<th>Hodgkin Lymphoma</th>
<th>Testis</th>
<th>Brain and Other Nervous System</th>
<th>Non-Hodgkin Lymphoma</th>
<th>Bones and Joints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ages 15-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>21.3</td>
<td>0.7*</td>
<td>23.1</td>
<td>0.7*</td>
<td>4.8</td>
<td>-1.9*</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>3.3</td>
<td>-0.4</td>
<td>3.3</td>
<td>-0.4</td>
<td>0.1</td>
<td>-5.2*</td>
</tr>
<tr>
<td>Testis</td>
<td>3.2</td>
<td>1.2*</td>
<td>3.7</td>
<td>1.2*</td>
<td>0.1</td>
<td>-5.2*</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>2.4</td>
<td>0.4</td>
<td>2.4</td>
<td>0.4</td>
<td>0.7</td>
<td>-0.9*</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>2.1</td>
<td>1.5*</td>
<td>2.4</td>
<td>1.5*</td>
<td>0.4</td>
<td>-3.2*</td>
</tr>
<tr>
<td>Bones and Joints</td>
<td>2.4</td>
<td>0.4</td>
<td>2.4</td>
<td>0.4</td>
<td>0.7</td>
<td>-0.9*</td>
</tr>
<tr>
<td>Ages 20-24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>33.4</td>
<td>0.5*</td>
<td>36.0</td>
<td>0.5*</td>
<td>6.5</td>
<td>-1.5*</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>4.9</td>
<td>-0.4*</td>
<td>4.7</td>
<td>-0.4*</td>
<td>0.5</td>
<td>-4.4*</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>2.7</td>
<td>1.5*</td>
<td>3.3</td>
<td>1.5*</td>
<td>0.6</td>
<td>-2.4*</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>8.9</td>
<td>1.0</td>
<td>10.2</td>
<td>-0.2</td>
<td>0.5</td>
<td>-3.6*</td>
</tr>
<tr>
<td>Ages 25-29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>50.2</td>
<td>0.7*</td>
<td>54.2</td>
<td>-0.1</td>
<td>8.7</td>
<td>-1.5*</td>
</tr>
<tr>
<td>Testis</td>
<td>5.2</td>
<td>0.7*</td>
<td>5.3</td>
<td>0.2</td>
<td>0.6</td>
<td>-2.8*</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>4.4</td>
<td>1.2</td>
<td>4.4</td>
<td>0.3</td>
<td>0.9</td>
<td>-2.0*</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>3.7</td>
<td>1.4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td>9.0</td>
<td>0.9*</td>
<td>10.1</td>
<td>0.9*</td>
<td>13.3</td>
<td>-1.4*</td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td>8.4</td>
<td>0.7*</td>
<td>8.5</td>
<td>0.1</td>
<td>1.0</td>
<td>-2.3*</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>7.1</td>
<td>0.9</td>
<td>6.0</td>
<td>-2.9</td>
<td>1.4</td>
<td>-1.4</td>
</tr>
<tr>
<td>Ages 30-34</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>71.0</td>
<td>0.9*</td>
<td>71.1</td>
<td>0.9*</td>
<td>13.3</td>
<td>-1.4*</td>
</tr>
<tr>
<td>Testis</td>
<td>8.4</td>
<td>0.1</td>
<td>8.5</td>
<td>0.1</td>
<td>1.0</td>
<td>-2.3*</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>7.1</td>
<td>0.9</td>
<td>6.0</td>
<td>-2.9</td>
<td>1.4</td>
<td>-1.4</td>
</tr>
<tr>
<td>Non-Hodgink Lymphoma</td>
<td>9.6</td>
<td>1.8*</td>
<td>12.2</td>
<td>0.4</td>
<td>0.5</td>
<td>-2.7*</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>7.7</td>
<td>1.1*</td>
<td>9.7</td>
<td>2.4*</td>
<td>2.3</td>
<td>-0.5</td>
</tr>
</tbody>
</table>

---

\(^a\) Rates are per 100,000.

\(^b\) SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

\(^c\) US Mortality Files, National Center for Health Statistics, CDC.

\(^d\) Top 5 cancer sites selected based on 1975-2014 rates for the age group.

\(^e\) The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2014.

\(\_\_\_\) Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

\(^*\) The AAPC is significantly different from zero (p<.05).
### Table 32.19
SEER Incidence and U.S. Mortality Rates and Trends for the Top 5 Cancer Sites by Age
All Races, Females, 1975-2014

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate</td>
<td>AAPC</td>
<td>Rate</td>
<td>AAPC</td>
</tr>
<tr>
<td>Ages 15-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>20.2</td>
<td>0.6*</td>
<td>22.4</td>
<td>0.6*</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>3.6</td>
<td>-0.6*</td>
<td>3.2</td>
<td>-0.6*</td>
</tr>
<tr>
<td>Thyroid</td>
<td>3.3</td>
<td>3.0*</td>
<td>4.8</td>
<td>8.8*</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>1.8</td>
<td>0.6</td>
<td>2.0</td>
<td>0.6</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>1.8</td>
<td>0.4</td>
<td>1.7</td>
<td>0.4</td>
</tr>
<tr>
<td>Ovary</td>
<td>1.5</td>
<td>-0.1</td>
<td>1.5</td>
<td>-0.1</td>
</tr>
<tr>
<td>Ages 20-24</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>35.7</td>
<td>0.7*</td>
<td>41.0</td>
<td>1.1*</td>
</tr>
<tr>
<td>Thyroid</td>
<td>7.5</td>
<td>2.2*</td>
<td>10.3</td>
<td>2.2*</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>5.6</td>
<td>1.4*</td>
<td>6.5</td>
<td>1.4*</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>5.0</td>
<td>0.7</td>
<td>5.0</td>
<td>-0.7</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>2.0</td>
<td>1.3*</td>
<td>2.5</td>
<td>1.3*</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>2.0</td>
<td>-3.2</td>
<td>1.2</td>
<td>-5.3*</td>
</tr>
<tr>
<td>Ages 25-29</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>62.0</td>
<td>0.7*</td>
<td>70.6</td>
<td>1.0*</td>
</tr>
<tr>
<td>Thyroid</td>
<td>11.9</td>
<td>2.3*</td>
<td>18.2</td>
<td>4.1*</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>9.7</td>
<td>1.0*</td>
<td>11.7</td>
<td>-2.0</td>
</tr>
<tr>
<td>Breast</td>
<td>8.4</td>
<td>0.5</td>
<td>9.0</td>
<td>3.6*</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>6.8</td>
<td>-2.1</td>
<td>4.5</td>
<td>-3.0*</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>4.6</td>
<td>0.1</td>
<td>4.6</td>
<td>0.1</td>
</tr>
<tr>
<td>Ages 30-34</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>101.4</td>
<td>0.8*</td>
<td>116.6</td>
<td>1.4*</td>
</tr>
<tr>
<td>Breast</td>
<td>26.8</td>
<td>0.1</td>
<td>27.5</td>
<td>0.1</td>
</tr>
<tr>
<td>Thyroid</td>
<td>15.1</td>
<td>2.6*</td>
<td>24.8</td>
<td>2.4</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>12.9</td>
<td>2.2*</td>
<td>15.0</td>
<td>1.0*</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>11.5</td>
<td>-1.2*</td>
<td>9.3</td>
<td>-1.2*</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>3.7</td>
<td>0.1</td>
<td>3.8</td>
<td>-3.8*</td>
</tr>
<tr>
<td>Ages 35-39</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Malignant Cancers</td>
<td>167.0</td>
<td>0.8*</td>
<td>185.5</td>
<td>1.1*</td>
</tr>
<tr>
<td>Breast</td>
<td>63.0</td>
<td>0.4*</td>
<td>63.5</td>
<td>0.3*</td>
</tr>
<tr>
<td>Thyroid</td>
<td>18.0</td>
<td>4.0*</td>
<td>31.1</td>
<td>5.5*</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>15.9</td>
<td>1.8</td>
<td>18.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>14.1</td>
<td>-1.2*</td>
<td>12.4</td>
<td>-1.2*</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>7.0</td>
<td>1.1*</td>
<td>8.8</td>
<td>2.8*</td>
</tr>
</tbody>
</table>

Rates are per 100,000.

- SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
- US Mortality Files, National Center for Health Statistics, CDC.
- Top 5 cancer sites selected based on 1975-2014 rates for the age group.
- The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2014.
- The AAPC could not be calculated due to insufficient data.
- The AAPC is significantly different from zero (p<.05).
### Table 32.20

SEER® 5-Year Relative Survival for the Top 5 Cancer Sites® by Age  
All Races, Both Sexes, 1975-2013

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hodgkin Lymphoma</td>
<td>92.5</td>
<td>67.6</td>
<td>69.3</td>
<td>94.2</td>
<td>96.2</td>
<td>97.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brain and Other Nervous System</td>
<td>73.5</td>
<td>62.3</td>
<td>70.0</td>
<td>78.0</td>
<td>76.8</td>
<td>76.8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thyroid</td>
<td>98.9</td>
<td>99.2</td>
<td>98.9</td>
<td>98.8</td>
<td>98.4</td>
<td>99.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-Hodkin Lymphoma</td>
<td>72.8</td>
<td>51.4</td>
<td>69.3</td>
<td>72.0</td>
<td>78.9</td>
<td>85.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Testis</td>
<td>90.4</td>
<td>77.2</td>
<td>91.8</td>
<td>90.1</td>
<td>95.1</td>
<td>93.9</td>
<td></td>
</tr>
<tr>
<td>Ages 20-24</td>
<td>All Malignant Cancers</td>
<td>81.3</td>
<td>74.7</td>
<td>78.5</td>
<td>81.1</td>
<td>85.0</td>
<td>87.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hodgkin Lymphoma</td>
<td>90.8</td>
<td>85.1</td>
<td>89.8</td>
<td>91.0</td>
<td>94.2</td>
<td>95.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Testis</td>
<td>92.6</td>
<td>84.7</td>
<td>90.5</td>
<td>95.0</td>
<td>96.4</td>
<td>95.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thyroid</td>
<td>99.7</td>
<td>99.6</td>
<td>99.6</td>
<td>99.3</td>
<td>99.5</td>
<td>99.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Melanoma of the Skin</td>
<td>93.0</td>
<td>85.8</td>
<td>90.6</td>
<td>94.5</td>
<td>96.6</td>
<td>97.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brain and Other Nervous System</td>
<td>67.8</td>
<td>59.1</td>
<td>61.2</td>
<td>71.5</td>
<td>68.7</td>
<td>80.8</td>
<td></td>
</tr>
<tr>
<td>Ages 25-29</td>
<td>All Malignant Cancers</td>
<td>80.0</td>
<td>76.7</td>
<td>74.0</td>
<td>77.4</td>
<td>85.1</td>
<td>87.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Melanoma of the Skin</td>
<td>93.4</td>
<td>88.1</td>
<td>91.6</td>
<td>94.1</td>
<td>96.4</td>
<td>95.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thyroid</td>
<td>99.7</td>
<td>99.7</td>
<td>99.3</td>
<td>99.9</td>
<td>99.7</td>
<td>99.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Testis</td>
<td>95.1</td>
<td>88.1</td>
<td>95.1</td>
<td>96.1</td>
<td>97.6</td>
<td>96.8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hodgkin Lymphoma</td>
<td>90.5</td>
<td>85.3</td>
<td>89.1</td>
<td>92.0</td>
<td>92.7</td>
<td>94.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breast</td>
<td>74.7</td>
<td>69.4</td>
<td>68.3</td>
<td>73.1</td>
<td>84.0</td>
<td>82.1</td>
<td></td>
</tr>
<tr>
<td>Ages 30-34</td>
<td>All Malignant Cancers</td>
<td>76.4</td>
<td>73.5</td>
<td>68.4</td>
<td>71.9</td>
<td>83.3</td>
<td>86.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breast</td>
<td>77.6</td>
<td>70.0</td>
<td>72.9</td>
<td>77.5</td>
<td>83.9</td>
<td>86.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Melanoma of the Skin</td>
<td>92.7</td>
<td>86.5</td>
<td>90.5</td>
<td>93.5</td>
<td>95.9</td>
<td>96.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thyroid</td>
<td>99.7</td>
<td>99.5</td>
<td>99.5</td>
<td>99.8</td>
<td>99.8</td>
<td>99.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Testis</td>
<td>95.7</td>
<td>92.0</td>
<td>95.6</td>
<td>96.0</td>
<td>95.9</td>
<td>97.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cervix Uteri</td>
<td>84.7</td>
<td>84.3</td>
<td>83.1</td>
<td>85.1</td>
<td>86.9</td>
<td>84.4</td>
<td></td>
</tr>
<tr>
<td>Ages 35-39</td>
<td>All Malignant Cancers</td>
<td>74.3</td>
<td>68.0</td>
<td>65.8</td>
<td>71.5</td>
<td>80.8</td>
<td>84.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breast</td>
<td>81.7</td>
<td>74.9</td>
<td>76.1</td>
<td>82.7</td>
<td>86.2</td>
<td>87.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Melanoma of the Skin</td>
<td>92.5</td>
<td>87.5</td>
<td>90.0</td>
<td>92.5</td>
<td>94.9</td>
<td>95.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thyroid</td>
<td>99.5</td>
<td>99.0</td>
<td>99.2</td>
<td>99.4</td>
<td>99.4</td>
<td>99.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-Hodkin Lymphoma</td>
<td>64.5</td>
<td>65.9</td>
<td>51.6</td>
<td>52.6</td>
<td>73.7</td>
<td>85.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Colon and Rectum</td>
<td>63.5</td>
<td>54.8</td>
<td>56.7</td>
<td>61.6</td>
<td>69.5</td>
<td>69.4</td>
<td></td>
</tr>
</tbody>
</table>

---

a  SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

b  Top 5 cancer sites selected based on 1975-2013 SEER 9 Incidence rates for the age group.

-  Statistic could not be calculated due to fewer than 25 cases during the time period.
### Table 32.21

SEER* 5-Year Relative Survival for the Top 5 Cancer Sites\(^b\) by Age

All Races, Males, 1975-2013

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All Malignant Cancers</td>
<td>74.3</td>
<td>62.4</td>
<td>71.2</td>
<td>75.6</td>
<td>78.7</td>
<td>82.5</td>
<td></td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>91.6</td>
<td>86.8</td>
<td>87.4</td>
<td>93.2</td>
<td>97.1</td>
<td>95.5</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>90.4</td>
<td>77.2</td>
<td>91.8</td>
<td>90.1</td>
<td>95.1</td>
<td>93.9</td>
<td></td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>70.7</td>
<td>58.3</td>
<td>67.6</td>
<td>76.2</td>
<td>75.0</td>
<td>76.1</td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>70.7</td>
<td>45.2</td>
<td>70.8</td>
<td>70.4</td>
<td>74.5</td>
<td>86.4</td>
<td></td>
</tr>
<tr>
<td>Bones and Joints</td>
<td>58.5</td>
<td>42.0</td>
<td>53.0</td>
<td>64.3</td>
<td>65.9</td>
<td>66.0</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All Malignant Cancers</td>
<td>76.9</td>
<td>69.5</td>
<td>72.3</td>
<td>76.7</td>
<td>82.6</td>
<td>83.9</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>92.6</td>
<td>84.7</td>
<td>90.5</td>
<td>95.0</td>
<td>96.4</td>
<td>95.3</td>
<td></td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>89.0</td>
<td>83.5</td>
<td>86.1</td>
<td>90.0</td>
<td>94.3</td>
<td>94.1</td>
<td></td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>86.8</td>
<td>77.0</td>
<td>82.0</td>
<td>88.6</td>
<td>93.9</td>
<td>95.3</td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>66.9</td>
<td>55.1</td>
<td>55.4</td>
<td>56.5</td>
<td>80.9</td>
<td>79.8</td>
<td></td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>66.4</td>
<td>54.8</td>
<td>59.6</td>
<td>74.5</td>
<td>68.9</td>
<td>76.8</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All Malignant Cancers</td>
<td>73.9</td>
<td>71.3</td>
<td>65.2</td>
<td>69.9</td>
<td>81.4</td>
<td>84.5</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>95.1</td>
<td>88.1</td>
<td>95.1</td>
<td>96.1</td>
<td>97.6</td>
<td>96.8</td>
<td></td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>88.5</td>
<td>82.6</td>
<td>87.2</td>
<td>89.5</td>
<td>92.6</td>
<td>90.3</td>
<td></td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>88.4</td>
<td>84.1</td>
<td>85.5</td>
<td>89.5</td>
<td>91.6</td>
<td>93.3</td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>59.4</td>
<td>57.3</td>
<td>46.4</td>
<td>47.3</td>
<td>73.5</td>
<td>81.0</td>
<td></td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td>15.9</td>
<td>-</td>
<td>9.1</td>
<td>12.0</td>
<td>44.3</td>
<td>67.2</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All Malignant Cancers</td>
<td>68.3</td>
<td>68.6</td>
<td>56.5</td>
<td>60.9</td>
<td>79.6</td>
<td>83.7</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>95.7</td>
<td>92.0</td>
<td>95.6</td>
<td>96.0</td>
<td>95.9</td>
<td>97.4</td>
<td></td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>88.5</td>
<td>79.2</td>
<td>85.4</td>
<td>90.6</td>
<td>93.1</td>
<td>93.8</td>
<td></td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td>18.7</td>
<td>34.8</td>
<td>8.4</td>
<td>19.6</td>
<td>54.4</td>
<td>70.5</td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>55.6</td>
<td>69.8</td>
<td>41.2</td>
<td>39.6</td>
<td>72.3</td>
<td>81.6</td>
<td></td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>87.3</td>
<td>78.7</td>
<td>83.3</td>
<td>86.9</td>
<td>93.7</td>
<td>92.6</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All Malignant Cancers</td>
<td>64.3</td>
<td>59.6</td>
<td>51.9</td>
<td>59.1</td>
<td>74.6</td>
<td>79.4</td>
<td></td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>88.4</td>
<td>82.2</td>
<td>85.3</td>
<td>88.5</td>
<td>91.2</td>
<td>94.0</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>96.3</td>
<td>92.1</td>
<td>95.0</td>
<td>96.9</td>
<td>97.0</td>
<td>97.5</td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>57.0</td>
<td>61.8</td>
<td>43.7</td>
<td>45.2</td>
<td>67.3</td>
<td>81.2</td>
<td></td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td>19.4</td>
<td>-</td>
<td>6.8</td>
<td>19.0</td>
<td>61.2</td>
<td>75.6</td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>61.8</td>
<td>55.5</td>
<td>52.8</td>
<td>60.7</td>
<td>68.8</td>
<td>64.8</td>
<td></td>
</tr>
</tbody>
</table>

---

*a* SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

*b* Top 5 cancer sites selected based on 1975-2013 SEER 9 Incidence rates for the age group.

- Statistic could not be calculated due to fewer than 25 cases during the time period.
Table 32.22

SEER® 5-Year Relative Survival for the Top 5 Cancer Sites\textsuperscript{a} by Age
All Races, Females, 1975-2013

<table>
<thead>
<tr>
<th>Ages 15-19</th>
<th>All Malignant Cancers</th>
<th>5-year Relative Survival (Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hodgkin Lymphoma</td>
<td>83.1</td>
<td>76.0</td>
</tr>
<tr>
<td>Thyroid</td>
<td>93.4</td>
<td>89.7</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>77.4</td>
<td>68.1</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>95.5</td>
<td>88.2</td>
</tr>
<tr>
<td>Ovary</td>
<td>88.3</td>
<td>78.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ages 20-24</th>
<th>All Malignant Cancers</th>
<th>5-year Relative Survival (Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hodgkin Lymphoma</td>
<td>85.5</td>
<td>79.8</td>
</tr>
<tr>
<td>Thyroid</td>
<td>99.7</td>
<td>99.3</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>96.2</td>
<td>91.5</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>92.6</td>
<td>87.0</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>69.5</td>
<td>65.4</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>88.1</td>
<td>89.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ages 25-29</th>
<th>All Malignant Cancers</th>
<th>5-year Relative Survival (Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hodgkin Lymphoma</td>
<td>84.9</td>
<td>80.6</td>
</tr>
<tr>
<td>Thyroid</td>
<td>99.7</td>
<td>99.8</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>96.1</td>
<td>91.9</td>
</tr>
<tr>
<td>Breast</td>
<td>74.7</td>
<td>69.4</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>87.2</td>
<td>88.8</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>92.8</td>
<td>86.8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ages 30-34</th>
<th>All Malignant Cancers</th>
<th>5-year Relative Survival (Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hodgkin Lymphoma</td>
<td>82.1</td>
<td>76.3</td>
</tr>
<tr>
<td>Thyroid</td>
<td>77.6</td>
<td>69.9</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>99.8</td>
<td>99.3</td>
</tr>
<tr>
<td>Breast</td>
<td>95.6</td>
<td>92.1</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>84.7</td>
<td>84.3</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>91.5</td>
<td>85.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ages 35-39</th>
<th>All Malignant Cancers</th>
<th>5-year Relative Survival (Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hodgkin Lymphoma</td>
<td>80.4</td>
<td>72.3</td>
</tr>
<tr>
<td>Thyroid</td>
<td>81.7</td>
<td>74.8</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>99.7</td>
<td>99.3</td>
</tr>
<tr>
<td>Breast</td>
<td>95.7</td>
<td>92.3</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>81.6</td>
<td>79.5</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>90.2</td>
<td>92.0</td>
</tr>
</tbody>
</table>

\textsuperscript{a} SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

\textsuperscript{b} Top 5 cancer sites selected based on 1975-2013 SEER 9 Incidence rates for the age group.

\textsuperscript{-} Statistic could not be calculated due to fewer than 25 cases during the time period.